Main Text {#sec1}
=========

Introduction {#sec1.1}
------------

The recent emergence and rapid global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the resulting coronavirus disease 2019 (COVID-19) poses an unprecedented health crisis that was declared a pandemic by the World Health Organization (WHO) on March 11, 2020. The origin of SARS-CoV-2 was traced to the city of Wuhan in the province of Hubei, China, where a cluster of viral pneumonia cases was first detected, many in connection with the Huanan Seafood Wholesale Market. China reported this outbreak to the WHO on December 31, 2019 and soon after identified the causative pathogen as a betacoronavirus with high sequence homology to bat coronaviruses (CoVs) using angiotensin-converting enzyme 2 (ACE2) receptor as the dominant mechanism of cell entry ([@bib183], [@bib285]). Following a likely zoonotic spillover, human-to-human transmission events were confirmed with clinical presentations ranging from no symptoms to mild fever, cough, and dyspnea to cytokine storm, respiratory failure, and death. SARS-CoV-2 is also closely related to SARS (retrospectively named SARS-CoV-1) and Middle Eastern respiratory syndrome (MERS) CoVs, causing zoonotic epidemic and local outbreaks in 2003 and 2012, respectively ([@bib76]). While SARS-CoV-2 is not as lethal as SARS-CoV-1 or MERS-CoV ([@bib91]), the considerable spread of the current pandemic has brought tremendous pressure and disastrous consequences for public health and medical systems worldwide.

The scientific response to the crisis has been extraordinary, with a plethora of COVID-19 studies posted in preprint servers in an attempt to rapidly unravel the pathogenesis of COVID-19 and potential therapeutic strategies. In response, trainees and faculty members of the Precision Immunology Institute at the Icahn School of Medicine at Mount Sinai (PrIISM) have initiated an institutional effort to critically review the preprint literature ([@bib277]), together with peer-reviewed articles published in traditional journals, and summarize the current state of science on the fast-evolving field of COVID-19 immunology. We thematically focus on the innate and adaptive immune responses to SARS-CoV-2 and related CoVs, clinical studies and prognostic laboratory correlates, current therapeutic strategies, prospective clinical trials, and vaccine approaches.

Innate Immune Sensing of SARS-CoV-2 {#sec1.2}
-----------------------------------

Innate immune sensing serves as the first line of antiviral defense and is essential for immunity to viruses. To date, our understanding of the specific innate immune response to SARS-CoV-2 is extremely limited. However, the virus-host interactions involving SARS-CoV-2 are likely to recapitulate many of those involving other CoVs, given the shared sequence homology among CoVs and the conserved mechanisms of innate immune signaling. In the case of RNA viruses such as SARS-CoV-2, these pathways are initiated through the engagement of pattern-recognition receptors (PRRs) by viral single-stranded RNA (ssRNA) and double-stranded RNA (dsRNA) via cytosolic RIG-I like receptors (RLRs) and extracellular and endosomal Toll-like receptors (TLRs). Upon PRR activation, downstream signaling cascades trigger the secretion of cytokines. Among these, type I/III interferons (IFNs) are considered the most important for antiviral defense, but other cytokines, such as proinflammatory tumor necrosis factor alpha (TNF-α), and interleukin-1 (IL-1), IL-6, and IL-18 are also released. Together, they induce antiviral programs in target cells and potentiate the adaptive immune response. If present early and properly localized, IFN-I can effectively limit CoV infection ([@bib47], [@bib48]). Early evidence demonstrated that SARS-CoV-2 is sensitive to IFN-I/III pretreatment *in vitro*, perhaps to a greater degree than SARS-CoV-1 ([@bib22], [@bib179], [@bib186], [@bib248]). However, the specific IFN-stimulated genes (ISGs) that mediate these protective effects are still being elucidated. Lymphocyte antigen 6 complex locus E (LY6E) has been shown to interfere with SARS-CoV-2 spike (S) protein-mediated membrane fusion ([@bib216], [@bib346]). Likely, the IFN-induced transmembrane family (IFITM) proteins inhibit SARS-CoV-2 entry, as demonstrated for SARS-CoV-1 ([@bib130]), although their action in promoting infection has also been described for other CoVs ([@bib342], [@bib343]).

### Evasion of Innate Sensing by Coronaviruses {#sec1.2.1}

As these cytokines represent a major barrier to viral infection, CoVs have evolved several mechanisms to inhibit IFN-I induction and signaling. Numerous studies have demonstrated that SARS-CoV-1 suppresses IFN release *in vitro* and *in vivo* ([@bib32], [@bib194], [@bib242], [@bib298]). SARS-CoV-2 likely achieves a similar effect, as suggested by the lack of robust type I/III IFN signatures from infected cell lines, primary bronchial cells, and a ferret model ([@bib22]). In fact, patients with severe COVID-19 demonstrate remarkably impaired IFN-I signatures as compared to mild or moderate cases ([@bib120]). As is often the case, there are multiple mechanisms of evasion for CoVs, with viral factors antagonizing each step of the pathway from PRR sensing and cytokine secretion to IFN signal transduction ([Figure 1](#fig1){ref-type="fig"} ).Figure 1Mechanisms of Host Innate Immune Response and Coronaviruses AntagonismOverview of innate immune sensing (left) and interferon signaling (right), annotated with the known mechanisms by which SARS-CoV-1 and MERS-CoV antagonize the pathways (red).

CoV-mediated antagonism of innate immunity begins with evasion of PRR sensing. ssRNA viruses, like CoVs, form dsRNA intermediates during their replication, which can be detected by TLR3 in the endosome and RIG-I, MDA5, and PKR in the cytosol. ssRNA may also be detected by TLR7 or TLR8 and potentially RIG-I and PKR. CoVs are known to avoid PRR activation by either avoiding recognition altogether or antagonizing PRR action ([@bib24], [@bib50], [@bib78], [@bib119], [@bib139], [@bib149]). To evade PRRs, dsRNA is first shielded by membrane-bound compartments that form during viral replication of SARS-CoV-1 ([@bib149]). In addition, viral RNA is guanosine-capped and methylated at the 5′ end by CoVs non-structural proteins (NSPs) 10, 13, 14, and 16 ([@bib24], [@bib50], [@bib139]), thereby resembling host mRNA to promote translation, prevent degradation, and evade RLR sensing. Finally, CoVs also encode an endoribonuclease, NSP15, that cleaves 5′ polyuridines formed during viral replication, which would otherwise be detected by MDA5 ([@bib78], [@bib119]). CoVs have evolved additional strategies to impede activation of PRRs. SARS-CoV-1 N-protein prevents TRIM25 activation of RIG-I ([@bib128]). Likewise, MERS-CoV NS4a, which itself binds dsRNA, impedes PKR activation ([@bib71], [@bib224]) and inhibits PACT, an activator of RLRs ([@bib203], [@bib243]). Additionally, MERS-CoV NS4b antagonizes RNaseL, another activator of RLRs ([@bib270]). The role of other PRRs remains unclear. For example, SARS-CoV-1 papain-like protease (PLP) antagonizes STING, suggesting that self-DNA may also represent an important trigger ([@bib252]). The extent to which SARS-CoV-2 homologs overlap in these functions is currently unknown.

Following activation, RLR and TLRs induce signaling cascades, leading to the phosphorylation of transcription factors, such as NF-kB and the interferon-regulatory factor family (IRF), ultimately leading to transcription of IFN and proinflammatory cytokines. Although no experimental studies have delineated the precise functions of SARS-CoV-2 proteins, proteomic studies have demonstrated interactions between viral proteins and PRR signaling cascades. SARS-CoV-2 ORF9b indirectly interacts with the signaling adaptor MAVS via its association with Tom70 ([@bib114]), consistent with prior reports that SARS-CoV-1 ORF9b suppresses MAVS signaling ([@bib238]). Furthermore, SARS-CoV-2 NSP13 interacts with signaling intermediate TBK1, and NSP15 is associated with RNF41, an activator of TBK1 and IRF3 ([@bib114]). Similarly, SARS-CoV-1 M protein is known to inhibit the TBK1 signaling complex ([@bib242]), as does MERS-CoV ORF4b ([@bib322]). Other proteins, including SARS-CoV-1 PLP, N, ORF3b, and ORF6, block IRF3 phosphorylation and nuclear translocation ([@bib79], [@bib151]). NF-kB is also inhibited by CoV proteins. These include SARS-CoV-1 PLP ([@bib98]) and MERS-CoV ORF4b and ORF5 ([@bib35], [@bib192]). Finally, SARS-CoV-1 NSP1 ([@bib129], [@bib144]) and MERS-CoV NSP1 ([@bib178]) initiate general inhibition of host transcription and translation, thus limiting antiviral defenses nonspecifically.

To prevent signaling downstream of IFN release, CoV proteins inhibit several steps of the signal transduction pathway that bridge the receptor subunits (IFNAR1 and IFNAR2) to the STAT proteins that activate transcription. For SARS-CoV-1, these mechanisms include IFNAR1 degradation by ORF3a ([@bib194]), decreased STAT1 phosphorylation by NSP1 ([@bib298]), and antagonism of STAT1 nuclear translocation by ORF6 ([@bib97], [@bib151]). However, SARS-CoV-2 ORF6 shares only 69% sequence homology with SARS-CoV-1, suggesting this function may not be conserved. In support of this notion, SARS-CoV-2 infection fails to limit STAT1 phosphorylation, unlike in SARS-CoV-1 infection ([@bib179]).

### Imbalance between Antiviral and Proinflammatory Responses {#sec1.2.2}

Taken together, the multiplicity of strategies developed by pathogenic CoVs to escape immune sensing, particularly the IFN-I pathway, suggests a critical role played by the dysregulation of IFN-I response in COVID-19 pathogenicity. Concordantly, animal models of SARS-CoV-1 and MERS-CoV infection indicate that failure to elicit an early IFN-I response correlates with the severity of disease ([@bib47]). Perhaps more importantly, these models demonstrate that timing is key, as IFN is protective early in disease but later becomes pathologic ([@bib47], [@bib48]). Perhaps interferon-induced upregulation of ACE2 in airway epithelia may contribute to this effect ([@bib361]). Furthermore, while pathogenic CoVs block IFN signaling, they may actively promote other inflammatory pathways contributing to pathology. For instance, SARS-CoV-1 ORF3a, ORF8b, and E proteins enhance inflammasome activation ([@bib51], [@bib204], [@bib239], [@bib244]), leading to secretion of IL-1β and IL-18, which are likely to contribute to pathological inflammation. Similarly, SARS-CoV-2 NSP9 and NSP10 might induce IL-6 and IL-8 production, potentially by inhibition of NKRF, an endogenous NF-kB repressor ([@bib160]). Collectively, these proinflammatory processes likely contribute to the "cytokine storm" observed in COVID-19 patients and substantiate a role for targeted immunosuppressive treatment regimens. Moving forward, a clear understanding of the delicate balance between antiviral and inflammatory innate immune programs will be essential to developing effective biomarkers and therapeutics for COVID-19.

Myeloid Cells {#sec1.3}
-------------

Mucosal immune responses to infectious agents are orchestrated and regulated by myeloid cells with specialized functions, which include conventional dendritic cells (cDCs), monocyte-derived DCs (moDCs), plasmacytoid DCs (pDCs), and macrophages ([@bib117]). A growing body of evidence points to dysregulated myeloid responses that potentially drive the COVID-19 hallmark syndromes, such as acute respiratory distress syndrome (ARDS), cytokine release syndrome (CRS) and lymphopenia ([@bib191]).

### Myeloid Characterization in COVID-19 {#sec1.3.1}

Flow cytometric analyses of peripheral blood mononuclear cells (PBMCs) from symptomatic COVID-19 patients have shown a significant influx of granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing, activated CD4^+^ T cells and CD14^+^HLA-DR^lo^ inflammatory monocytes (IMs) ([@bib109], [@bib338], [@bib355]). This matches single-cell transcriptomic (scRNA-seq) data demonstrating CD14^+^IL-1β^+^ monocytic expansion ([@bib118], [@bib300]), interferon-mitogen-activated protein kinase (MAPK)-driven adaptive immune responses ([@bib134]), and IL-1β-associated inflammasome signatures ([@bib208]) in peripheral blood of COVID-19 patients, although systemic levels of IL-1β detected are conspicuously low ([@bib363]). Importantly, these immune signatures track with progression of clinical disease. scRNA-seq studies performed on pulmonary tissues of patients with severe COVID-19 disease have revealed an expansion of IMs and Ficolin-1^+^ monocyte-derived macrophages at the expense of tissue-resident reparative alveolar macrophages (AMs) ([@bib164]). The aforementioned study also observed signatures of IFN signaling and monocyte recruitment that likely contribute to the rapid decline in alveolar patency and promote ARDS. Although most of the clinical focus has been on pulmonary damage and mononuclear phagocyte (MNP) dysfunction therein, it is increasingly clear that COVID-19 likely presents systemic challenges in other organ sites, such as the ileum and kidneys. Understanding the role of non-pulmonary myeloid cells in tissue-specific pathology associated with COVID-19 will be important.

### Prior Knowledge from SARS-CoV-1, MERS-CoV, and Murine Coronaviruses {#sec1.3.2}

While data on COVID-19 patients continues to rapidly emerge, studies of myeloid cell dysfunction in SARS-CoV-1 and MERS-CoV can provide an important roadmap to understanding COVID-19 pathogenesis ([Figure 2](#fig2){ref-type="fig"} ). SARS-CoV-1 infection in mouse models results in an aberrant AM phenotype that limits DC trafficking and T cell activation ([@bib340]). Additionally, YM1^+^ FIZZ1^+^ alternative macrophages can increase airway hypersensitivity, thus exacerbating SARS-associated fibrosis ([@bib209]). Further, as described above, murine SARS-CoV-1 studies have demonstrated that delayed IFN-I signaling and inflammatory monocytes-macrophages promote lung cytokine and chemokine levels, vascular leakage, and impaired antigen-specific T cell responses, culminating in lethal disease ([@bib47]). The role played by prominent IFN-producing pDCs in SARS-CoV-2 control or pathogenesis warrants investigation, as they have been shown to be critical in murine CoV (MHV) control ([@bib43]). Longitudinal studies in SARS-CoV-2 models are awaited, but initial phenotypic studies in humanized hACE2 mice have shown the characteristic alveolar interstitial pneumonia, with infiltration of lymphocytes and monocytes and accumulation of macrophages in the alveolar lumen ([@bib16]), which recapitulates patient findings ([@bib318]). Lastly, non-human primate (NHP) studies and patient data on SARS-CoV-1 have also shown that virus spike-specific immunoglobulin G (IgG) responses can exacerbate acute lung injury due to repolarization of alveolar macrophages into proinflammatory phenotypes and enhanced recruitment of inflammatory monocyte via CCL2 and IL-8 ([@bib69], [@bib168]). However, the extent to which the antibody response contributes to disease pathophysiology remains to be confirmed.Figure 2SARS-CoV-2 Infection Results in Myeloid Cell Activation and Changes NK Cell FunctionBased on data from preliminary COVID-19 studies and earlier studies in related coronaviruses.IL-6, IL-1β, and IFN-I/III from infected pulmonary epithelia can induce inflammatory programs in resident (alternate) macrophages while recruiting inflammatory monocytes, as well as granulocytes and lymphocytes from circulation. Sustained IL-6 and TNF-ɑ by incoming monocytes can drive several hyperinflammation cascades. Inflammatory monocyte-derived macrophages can amplify dysfunctional responses in various ways (listed in top-left corner). The systemic CRS- and sHLH-like inflammatory response can induce neutrophilic NETosis and microthrombosis, aggravating COVID-19 severity. Other myeloid cells, such as pDCs, are purported to have an IFN-dependent role in viral control. Monocyte-derived CXCL9/10/11 might recruit NK cells from blood. Preliminary data suggest that the antiviral function of these NK cells might be regulated through crosstalk with SARS-infected cells and inflammatory monocytes.Dashed lines indicate pathways to be confirmed. Arg1, arginase 1; iNOS, inducible-nitric oxide synthase; Inflamm., inflammatory; Mono., monocytes; Macs, macrophages; Eosino, eosinophils; Neutro, neutrophils; NETosis, neutrophil extracellular trap cell death; SHLH, secondary hemophagocytic lymphohistiocytosis.

### Myeloid Cells Contribution to Pathogenic Inflammation {#sec1.3.3}

The initial mode of viral pathogen-associated signal (PAMP) recognition by innate cells has a major impact on downstream myeloid signaling and cytokine secretion ([@bib75]). While macrophages are somewhat susceptible to MERS-CoV and SARS-CoV-1 infection ([@bib215], [@bib352]), data do not suggest that they are infected by SARS-CoV-2, although one study reported ACE2 and SARS-CoV-2 nucleocapsid protein is expressed in lymph nodes and spleen-associated CD169^+^ macrophages of COVID-19 patients producing IL-6 ([@bib59]). Significantly elevated systemic levels of proinflammatory cytokine IL-6 have been reported in several COVID-19 patient cohorts and shown to correlate with disease severity ([@bib191]). Increased IL-6 can also be associated with higher levels of IL-2, IL-7, IFN-ɣ, and GM-CSF, as seen in secondary hemophagocytic lymphohistiocytosis. In response to viral infections, MNPs drive IL and IFN-I and IFN-III production resulting in inflammasome activation, induction of pathogenic Th1 and Th17 cell responses, recruitment of effector immune cells, and CRS pathology ([@bib219], [@bib257]). Independently, *in vitro* studies have demonstrated SARS-CoV-1 infection can induce intracellular stress pathways, resulting in NLRP3-dependent inflammasome activation and macrophage pyroptosis ([@bib51], [@bib239]). Functional studies are required to implicate these myeloid inflammasome pathways in COVID-19 lung pathology and to assess other immunogenic pathways such as RIPK1/3-dependent necroptosis ([@bib199]). In conclusion, the strength and duration of myeloid ISG)signaling potentially dictate COVID-19 disease severity, but rigorous studies are warranted to confirm this.

Lastly, more work is needed to ascertain the mechanistic role played by lung-resident and recruited granulocytes in SARS-CoV-2 control and pathogenesis ([@bib33], [@bib94]). In contrast to their early protective role, neutrophil NETosis and macrophage crosstalk can drive later-stage inflammatory cascades ([@bib18]), underscoring the overall pathogenic nature of damage-sensing host responses ([Figure 2](#fig2){ref-type="fig"}).

Collectively, the current knowledge of CoVs and SARS-CoV-2 infection, in particular, points to an inadvertent collusion involving myeloid cells in COVID-19 pathogenesis, despite their critical role in early sensing and antiviral responses.

Innate Lymphoid Cells {#sec1.4}
---------------------

Innate lymphoid cells (ILCs) are innate immune effector cells that lack the expression of rearranged antigen receptors (T cell receptor \[TCR\], B cell receptor \[BCR\]). The ILC family is divided into two main groups: the cytotoxic natural killer (NK) cells and the non-cytotoxic helper ILCs, which include ILC1, ILC2, and ILC3 ([@bib280]). Conventional NK cells include CD56^bright^CD16^−^ NK cells and CD56^dim^CD16^+^ cells, which are specialized in cytokine production or cytotoxicity, respectively.

### NK Cells Are Decreased in the Peripheral Blood of COVID-19 patients {#sec1.4.1}

Multiple studies have reported reduced numbers of NK cells in the peripheral blood of COVID-19 patients, which is associated with severity of the disease ([@bib247], [@bib295], [@bib330], [@bib351]). A recent scRNA-seq analysis revealed a transcriptomic signature for NK cells that was equally represented in lungs from patients and healthy donors ([@bib164]). The majority of lung NK cells are non-resident ([@bib106], [@bib188]), and CXCR3 has been shown to mediate NK cell infiltration upon influenza infection ([@bib42]). *In vitro*, CXCR3 ligands (CXCL9-11) are increased in SARS-CoV-2-infected human lung tissue ([@bib67]), and CXCR3-ligand-producing monocytes are expanded in the lungs of COVID-19 patients ([@bib164]). This suggests that the CXCR3 pathway might facilitate NK cell recruitment from the peripheral blood to the lungs in COVID-19 patients ([Figure 2](#fig2){ref-type="fig"}).

### NK Cell Activation Pathways in Antiviral Immunity {#sec1.4.2}

NK cells express inhibitory and activating receptors that regulate their cytotoxicity. They are therefore able to induce the lysis of virus-infected cells that upregulate virus-derived proteins, as well as stress-inducible ligands, which are then recognized by NK-cell-activating receptors, such as NKp46 ([@bib44], [@bib84], [@bib88], [@bib112]). Future studies should investigate the expression of NK receptor ligands on SARS-CoV-2-infected cells in order to better understand the mechanisms underlying NK cell activation in COVID-19 disease. Further, secretion of IgG1 and IgG3 antibodies during SARS-CoV-2 infection ([@bib8]) may induce CD56^dim^ CD16^+^ NK cell activation through Fc receptor recognition of antibodies either bound to surface antigens expressed on infected cells or to extracellular virions as immune complexes ([Figure 2](#fig2){ref-type="fig"}). This interaction might trigger both cytokine production by NK cells and lysis of infected cells through antibody-mediated cellular cytotoxicity (ADCC), as shown in influenza infection ([@bib281]). Emerging data highlight the capacity for NK-mediated ADCC in response to naturally isolated SARS-CoV-1 anti-S IgG that crossreacts with SARS-CoV-2 S glycoprotein when transfected into Chinese hamster ovary (CHO) cells ([@bib217]). These findings suggest that triggering NK cell activation may not only contribute to the resolution of infection, but also contribute to the cytokine storm in ARDS.

### Impairment of NK Cell Function in SARS-CoV-2 Infection {#sec1.4.3}

*Ex vivo* NK cells from peripheral blood of COVID-19 patients have reduced intracellular expression of CD107a, Ksp37, granzyme B, and granulysin, suggesting an impaired cytotoxicity, as well as an impaired production of chemokines, IFN-ɣ, and TNF-α ([@bib301], [@bib351]). Several pathways may contribute to the dysregulation of NK cells. While influenza virus infects NK cells and induces apoptosis ([@bib187]), lung NK cells do not express the entry receptor for SARS-CoV-2, ACE2, and are therefore unlikely to be directly infected by SARS-CoV-2 ([@bib275]). The majority of NK cells found in human lung display a mature CD16^+^KIR^+^CD56^dim^ phenotype and are able to induce cell cytotoxicity in response to loss of human leukocyte antigen (HLA) class I or through Fc receptor signaling, although to a lower extent than their peripheral blood counterpart ([@bib188]). Killer-immunoglobulin receptors (KIRs) are acquired during NK cell development alongside CD16 (FcRγIIIA) and are essential for NK cell licensing and subsequent capacity for cytolytic function ([@bib245]). Frequencies of NK cells expressing CD16 and/or KIRs are decreased in the blood following SARS-CoV-2 and SARS-CoV-1 infection, respectively ([@bib312], [@bib293]). Collectively, the data suggest either an impaired maturation of the NK compartment or migration of the mature, circulating NK cells into the lungs or other peripheral tissues of SARS-CoV-2-infected patients.

The immune checkpoint NKG2A is increased on NK cells and CD8 T cells from COVID-19 patients ([@bib351]). NKG2A inhibits cell cytotoxicity by binding the non-classical HLA-E molecule ([@bib25], [@bib27]), and this interaction is strongly correlated with poor control of HIV-1 infection ([@bib225]). Genes encoding the inhibitory receptors LAG3 and TIM3 are also upregulated in NK cells from COVID-19 patients ([@bib301], [@bib120]). Thus, increased immune checkpoints on NK cells might contribute to viral escape. Additionally, COVID-19 patients have higher plasma concentrations of IL-6 ([@bib133]), which significantly correlate with lower NK cell numbers ([@bib293], [@bib295]). *In vitro* stimulation by IL-6 and soluble IL-6 receptor has previously revealed impaired cytolytic functions (perforin and granzyme B production) by healthy donor NK cells, which can be restored following addition of tocilizumab (IL-6R blockade) ([@bib68]). TNF-α is also upregulated in the plasma of COVID-19 patients ([@bib133]), and ligand-receptor interaction analysis of peripheral blood scRNA-seq data suggests that monocyte-secreted TNF-α might bind to its receptors on NK cells ([@bib118]). TNF-α is known to contribute to NK cell differentiation ([@bib154]), which includes downregulation of NKp46 ([@bib138]), though no effect of TNF-α or IL-6 on NK cell-mediated ADCC has been reported so far. Collectively, these data suggest that crosstalk with monocytes might impair NK cell recognition and killing of SARS-CoV-2-infected cells, and antibodies targeting IL-6 and TNF-signaling may benefit enhanced NK cell functions in COVID-19 patients ([Figure 2](#fig2){ref-type="fig"}).

### Relevance for Helper ILCs in SARS-CoV-2 Infection {#sec1.4.4}

No studies, to date, have reported ILC1, ILC2, or ILC3 functions in SARS-CoV-2 infection. All three subsets are present in healthy lung ([@bib74], [@bib332]). ILC2s are essential for the improvement of lung function following influenza infection in mice through amphiregulin-mediated restoration of the airway epithelium and oxygen saturation ([@bib197]). However, ILC2s also produce IL-13, contributing to the recruitment of macrophages to the lung and influenza-induced airway hyperreactivity ([@bib46]). Indeed, ILCs are involved in the polarization of alveolar macrophages, either toward a M1-like phenotype (ILC1 and ILC3) or a M2-like phenotype (ILC2) ([@bib147]). Given the increased IL-13 concentrations ([@bib133]) and the dysregulation of the macrophage compartment observed in COVID-19 patients, the role played by ILCs in SARS-CoV-2 infection warrants further investigation.

T Cell Responses {#sec1.5}
----------------

T cells play a fundamental role in viral infections: CD4 T cells provide B cell help for antibody production and orchestrate the response of other immune cells, whereas CD8 T cells kill infected cells to reduce the viral burden. However, dysregulated T cell responses can result in immunopathology. To better understand the role of T cell responses in SARS-CoV-2 infection, the pursuit of two major questions is imperative: (1) what is the contribution of T cells to initial virus control and tissue damage in the context of COVID-19, and (2) how do memory T cells established thereafter contribute to protective immunity upon reinfection? Some tentative answers are beginning to emerge.

### Overall Reduction of CD4 and CD8 T Cell Counts in Peripheral Blood {#sec1.5.1}

Similar to earlier observations about SARS-CoV-1 infection ([@bib123]), several current reports emphasize the occurrence of lymphopenia with drastically reduced numbers of both CD4 and CD8 T cells in moderate and severe COVID-19 cases ([Figure 3](#fig3){ref-type="fig"} ) ([@bib54], [@bib202], [@bib293], [@bib333], [@bib351]). The extent of lymphopenia---most striking for CD8 T cells in patients admitted to the intensive care unit (ICU)---seemingly correlates with COVID-19-associated disease severity and mortality ([@bib54], [@bib80], [@bib170], [@bib171], [@bib255], [@bib293], [@bib295], [@bib333], [@bib356]). Patients with mild symptoms, however, typically present with normal or slightly higher T cell counts ([@bib169], [@bib267]). The cause of peripheral T cell loss in moderate to severe COVID-19, though a phenomenon also observed in other viral infections, remains elusive, and direct viral infection of T cells, in contrast to MERS-CoV ([@bib66]), has not been reported.Figure 3Working Model for T Cell Responses to SARS-CoV-2: Changes in Peripheral Blood T Cell Frequencies and PhenotypeA decrease in peripheral blood T cells associated with disease severity and inflammation is now well documented in COVID-19. Several studies report increased numbers of activated CD4 and CD8 T cells, which display a trend toward an exhausted phenotype in persistent COVID-19, based on continuous and upregulated expression of inhibitory markers as well as potential reduced polyfunctionality and cytotoxicity. In severe disease, production of specific inflammatory cytokines by CD4 T cells has also been reported. This working model needs to be confirmed and expanded on in future studies to assess virus-specific T cell responses both in peripheral blood and in tissues. In addition, larger and more defined patient cohorts with longitudinal data are required to define the relationship between disease severity and T cell phenotype.IL, interleukin; IFN, interferon; TNF, tumor necrosis factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; GzmA/B, granzyme A/granzyme B; Prf1, perforin.

Several mechanisms likely contribute to the reduced number of T cells in the blood, including effects from the inflammatory cytokine milieu. Indeed, lymphopenia seems to correlate with serum IL-6, IL-10, and TNF-α ([@bib80], [@bib284]), while convalescent patients were found to have restored bulk T cell frequencies paired with overall lower proinflammatory cytokine levels ([@bib57], [@bib80], [@bib169], [@bib170], [@bib351]). Cytokines such as IFN-I and TNF-α may inhibit T cell recirculation in blood by promoting retention in lymphoid organs and attachment to endothelium ([@bib145], [@bib241]). However, in an autopsy study examining the spleens and hilar lymph nodes of six patients who succumbed to COVID-19, Chen et al. observed extensive cell death of lymphocytes and suggested potential roles for IL-6 as well as Fas-FasL interactions ([@bib59]). In support of this hypothesis, the IL-6 receptor antagonist tocilizumab was found to increase the number of circulating lymphocytes ([@bib109]). T cell recruitment to sites of infection may also reduce their presence in the peripheral blood compartment. scRNA-seq analysis of bronchoalveolar lavage (BAL) fluid of COVID-19 patients revealed an increase in CD8 T cell infiltrate with clonal expansion ([@bib164]). Likewise, post-mortem examination of a patient who succumbed to ARDS following SARS-CoV-2 infection showed extensive lymphocyte infiltration in the lungs ([@bib318]). However, another study that examined post-mortem biopsies from four COVID-19 patients only found neutrophilic infiltration ([@bib271]). Further studies are therefore needed to better determine the cause and impact of the commonly observed lymphopenia in COVID-19 patients.

### Induction of Antiviral T Cell Responses {#sec1.5.2}

Available information about SARS-CoV-1-specific T cell immunity may serve as an orientation for further understanding of SARS-CoV-2 infection. Immunogenic T cell epitopes are distributed across several SARS-CoV-1 proteins (S, N, and M, as well as ORF3), although CD4 T cell responses were more restricted to the S protein ([@bib159]). In SARS-CoV-1 survivors, the magnitude and frequency of specific CD8 memory T cells exceeded that of CD4 memory T cells, and virus-specific T cells persisted for at least 6--11 years, suggesting that T cells may confer long-term immunity ([@bib200], [@bib258]). Limited data from viremic SARS patients further indicated that virus-specific CD4 T cell populations might be associated with a more severe disease course, since lethal outcomes correlated with elevated Th2 cell (IL-4, IL-5, IL-10) serum cytokines ([@bib159]). However, the quality of CD4 T cell responses needs to be further characterized to understand associations with disease severity. Few studies have thus far characterized specific T cell immunity in SARS-CoV-2 infection. In 12 patients recovering from mild COVID-19, robust T cell responses specific for viral N, M, and S proteins were detected by IFN-γ ELISPOT, weakly correlated with neutralizing antibody concentrations (similar to convalescent SARS-CoV-1 patients; [@bib159]), and subsequently contracted with only N-specific T cells detectable in about one-third of the cases post recovery ([@bib83]). In a second study, PBMCs from COVID-19 patients with moderate to severe ARDS were analyzed by flow cytometry approximately 2 weeks after ICU admission ([@bib299]). Both virus-specific CD4 and CD8 T cells were detected in all patients at average frequencies of 1.4% and 1.3%, respectively, and very limited phenotyping according to CD45RA and CCR7 expression status characterized these cells predominantly as either CD4 Tcm (central memory) or CD8 Tem (effector memory) and Temra (effector memory RA) cells. This study is notable for the use of large complementary peptide pools comprising 1,095 SARS-Cov-2 epitopes (overlapping 15-mers for S protein as well as computationally predicted HLA-I- and -II-restricted epitopes for all other viral proteins) as antigen-specific stimuli that revealed a preferential specificity of both CD4 and CD8 T cells for S protein epitopes, with the former population modestly increasing over ∼10--30 days after initial onset of symptoms. A caveat, however, pertains to the identification of specific T cells by induced CD69 and CD137 co-expression, since upregulation of CD137 by CD4 T cells, in contrast to CD154, may preferentially capture regulatory T cells (Treg) ([@bib15]). Further analyses of S protein-specific T cells by ELISA demonstrated robust induction of IFN-γ, TNF-α, and IL-2 concomitant with lower levels of IL-5, IL-13, IL-9, IL-10, and IL-22. A third report focused on S-specific CD4 T cell responses in 18 patients with mild, severe, or critical COVID-19 using overlapping peptide pools and induced CD154 and CD137 co-expression as a readout for antiviral CD4 T cells. Such cells were present in 83% of cases and presented with enhanced CD38, HLA-DR, and Ki-67 expression indicative of recent *in vivo* activation ([@bib26]). Of note, the authors also detected low frequencies of S-reactive CD4 T cells in 34% of SARS-CoV-2 seronegative healthy control donors. However, these CD4 T cells lacked phenotypic markers of activation and were specific for C-terminal S protein epitopes that are highly similar to endemic human CoVs, suggesting that crossreactive CD4 memory T cells in some populations (e.g., children and younger patients that experience a higher incidence of hCoV infections) may be recruited into an amplified primary SARS-CoV-2-specific response ([@bib26]). Similarly, endemic CoV-specific CD4 T cells were previously shown to recognize SARS-CoV1 determinants ([@bib110]). How previous infections with endemic CoV may affect immune responses to SARS-CoV-2 will need to be further investigated.

Finally, in general accordance with the above findings on the induction of SARS-CoV-2-specific T cells, using TCR sequencing (TCR-seq), Huang et al. and Liao et al. reported greater TCR clonality of peripheral blood ([@bib134]) as well as BAL T cells ([@bib164]) in patients with mild versus severe COVID-19. Moving forward, a comprehensive identification of immunogenic SARS-CoV-2 epitopes recognized by T cells ([@bib34]), as well as further studies on convalescent patients who recovered from mild and severe disease, will be particularly important.

### T Cell Contribution to COVID-19 Hyperinflammation {#sec1.5.3}

While the induction of robust T cell immunity is likely essential for efficient virus control, dysregulated T cell responses may cause immunopathology and contribute to disease severity in COVID-19 patients ([Figure 3](#fig3){ref-type="fig"}). This is suggested in a study by Zhou et al., which reported a significantly increased PBMC frequency of polyclonal GM-CSF^+^ CD4 T cells capable of prodigious *ex vivo* IL-6 and IFN-γ production only in critically ill COVID-19 patients ([@bib356]). Of note, GM-CSF^+^ CD4 T cells have been previously implicated in inflammatory autoimmune diseases, such as multiple sclerosis or juvenile rheumatoid arthritis, and high levels of circulating GM-CSF^+^ CD4 T cells were found to be associated with poor outcomes in sepsis ([@bib131]). Additionally, two studies observed reduced frequencies of Treg cells in severe COVID-19 cases ([@bib54], [@bib220]). Since Treg cells have been shown to help resolve ARDS inflammation in mouse models ([@bib283]), a loss of Tregs might facilitate the development of COVID-19 lung immunopathology. Similarly, a reduction of γδ-T cells, a subset of T cells with apparent protective antiviral function in influenza pneumonia ([@bib82], [@bib349]), has been reported in severely sick COVID-19 patients ([@bib118], [@bib157]).

### Phenotype and Function of T Cell Subsets in COVID-19 {#sec1.5.4}

Currently, little is known about specific phenotypical and/or functional T cell changes associated with COVID-19. In the majority of preprints and peer-reviewed studies, there are reports of increased presence of activated T cells ([Figure 3](#fig3){ref-type="fig"}) characterized by expression of HLA-DR, CD38, CD69, CD25, CD44, and Ki-67 ([@bib26], [@bib83], [@bib118], [@bib164], [@bib267], [@bib323], [@bib350]). Generally, independent of COVID-19 disease severity, CD8 T cells seem to be more activated than CD4 T cells ([@bib220], [@bib267], [@bib323]), a finding that echoes stronger CD8 than CD4 T cell responses during SARS-CoV-1 ([@bib159]). Furthermore, in a case study of 10 COVID-19 patients, Diao et al. showed that levels of PD-1 increased from prodromal to symptomatic stages of the disease ([@bib80]). PD-1 expression is commonly associated with T cell exhaustion, but it is important to emphasize that PD-1 is primarily induced by TCR signaling; it is thus also expressed by activated effector T cells ([@bib4]).

In addition, several studies reported higher expression of various co-stimulatory and inhibitory molecules such as OX-40 and CD137 ([@bib356]), CTLA-4 and TIGIT ([@bib350]), and NKG2a ([@bib351]). Reduced numbers of CD28^+^ CD8 T cells ([@bib220]) as well as larger frequencies of PD-1^+^ TIM3^+^ CD8 T cells in ICU patients were also reported ([@bib356]). Expression of most of these markers was found to be higher in CD8 than in CD4 T cells, and levels tended to increase in severe versus non-severe cases, which may be due to differences in viral load. Cellular functionality was shown to be impaired in CD4 and CD8 T cells of critically ill patients, with reduced frequencies of polyfunctional T cells (producing more than one cytokine) as well as generally lower IFN-γ and TNF-α production following restimulation with phorbol myristate acetate (PMA) and ionomycin ([@bib54], [@bib350], [@bib351]). Similarly, Zheng et al. reported that CD8 T cells in severe COVID-19 appear less cytotoxic and effector-like with reduced CD107a degranulation and granzyme B (GzmB) production ([@bib351]). In contrast, a different study found that both GzmB and perforin were increased in CD8 T cells of severely sick patients ([@bib350]). In accordance with the latter observation, when compared to a moderate disease group, convalescent patients with resolved severe SARS-CoV-1 infection had significantly higher frequencies of polyfunctional T cells, with CD4 T cells producing more IFN-γ, TNF-α, and IL-2 and CD8 T cells producing more IFN-γ, TNF-α, and CD107a, respectively ([@bib159]). However, given the vigorous dynamics of acute T cell responses and potential differences in sample timing throughout disease course, these observations are not necessarily mutually exclusive. Accordingly, RNA sequencing (RNA-seq) data by Liao et al. showed that CD8 T cells in the BAL fluid of severe COVID-19 patients express cytotoxic genes such as *GZMA*, *GZMB*, and *GZMK* at higher levels, while *KLRC1* and *XCL1* are enriched in mild cases ([@bib164]).

In summary, T cells in severe COVID-19 seem to be more activated and may exhibit a trend toward exhaustion based on continuous expression of inhibitory markers such as PD-1 and TIM-3 as well as overall reduced polyfunctionality and cytotoxicity. Conversely, recovering patients were shown to have an increase in follicular helper CD4 T cells (T~FH~) as well as decreasing levels of inhibitory markers along with enhanced levels of effector molecules such as Gzm A, GzmB, and perforin ([@bib267], [@bib323], [@bib351]). Collectively, these studies provide a first glimpse into T cell dynamics in acute SARS-CoV-2 infection, but any conclusions have to be tempered at this stage on account of significant limitations in many of the current investigations.

B Cell Responses {#sec1.6}
----------------

### Acute B Cell and Antibody Responses {#sec1.6.1}

The humoral immune response is critical for the clearance of cytopathic viruses and is a major part of the memory response that prevents reinfection. SARS-CoV-2 elicits a robust B cell response, as evidenced by the rapid and near-universal detection of virus-specific IgM, IgG and IgA, and neutralizing IgG antibodies (nAbs) in the days following infection. The kinetics of the antibody response to SARS-CoV-2 are now reasonably well described ([@bib132]).

Similar to SARS-CoV-1 infection ([@bib127]), seroconversion occurs in most COVID-19 patients between 7 and 14 days after the onset of symptoms, and antibody titers persist in the weeks following virus clearance ([Figure 4](#fig4){ref-type="fig"} ) ([@bib121], [@bib181], [@bib207], [@bib256], [@bib303], [@bib309], [@bib344]). Antibodies binding the SARS-CoV-2 internal N protein and the external S glycoprotein are commonly detected ([@bib8], [@bib143], [@bib273]). The receptor binding domain (RBD) of the S protein is highly immunogenic, and antibodies binding this domain can be potently neutralizing, blocking virus interactions with the host entry receptor, ACE2 ([@bib143], [@bib309]). Anti-RBD nAbs are detected in most tested patients ([@bib143], [@bib273], [@bib309]). Although crossreactivity to SARS-CoV-1 S and N proteins and to MERS-CoV S protein was detected in plasma from COVID-19 patients, no crossreactivity was found to the RBD from SARS-CoV-1 or MERS-CoV. In addition, plasma from COVID-19 patients did not neutralize SARS-CoV-1 or MERS-CoV ([@bib143]).Figure 4Antibody-Mediated Immunity in SARS-CoV-2Virus-specific IgM and IgG are detectable in serum between 7 and 14 days after the onset of symptoms. Viral RNA is inversely correlated with neutralizing antibody titers. Higher titers have been observed in critically ill patients, but it is unknown whether antibody responses somehow contribute to pulmonary pathology. The SARS-CoV-1 humoral response is relatively short lived, and memory B cells may disappear altogether, suggesting that immunity with SARS-CoV-2 may wane 1--2 years after primary infection.

RBD-specific CD19^+^IgG^+^ memory B cells were single-cell sorted from a cohort of eight COVID-19 donors between days 9 and 28 after the onset of symptoms ([@bib143]). From their antibody gene sequences, 209 SARS-CoV-2-specific monoclonal antibodies were produced. The monoclonal antibodies had a diverse repertoire, relatively low or no somatic mutations, and variable binding reactivity, with dissociation constants reaching 10^−8^ to 10^−9^, similar to antibodies isolated during acute infections. Two potent neutralizing SARS-CoV-2 RBD-specific monoclonal antibodies were characterized that did not crossreact with the RBD of SARS-CoV-1 or MERS-CoV ([@bib143]). Together, these results demonstrate that antibody mediated neutralization is virus specific and likely driven by binding of epitopes within the RBD.

### B Cell Memory: Development and Lifespan {#sec1.6.2}

The B cell response to a virus serves not only to protect from the initial challenge, but also to offer extended immunity against reinfection. Following resolution of an infection, plasma cells formed during the acute and convalescent phases continue to secrete antibodies, giving rise to serological memory. Memory B cells that are also formed during the primary infection constitute the second arm of B cell memory. Memory B cells can quickly respond to a reinfection by generating new high-affinity plasma cells. Long-term protection is achieved through the induction of long-lived plasma cells and memory B cells.

There is great interest in understanding the lifespan of B cell memory responses to SARS-CoV-2. Protection from reinfection has direct medical and social consequences as the world works to develop vaccination strategies and resume normal activities. In COVID-19 patients, evidence of near-universal seroconversion and the lack of substantial descriptions of reinfection point to a robust antibody response, which, along with the T cell memory response, would offer protection to reinfection. Indeed, a case study of a single patient described induction of CD38^Hi^CD27^Hi^ antibody-secreting cells (ASCs), concomitant with an increase in circulating follicular T helper cells (Tfh) cells ([@bib267]), and a scRNA-seq study of PBMCs from critically ill and recently recovered individuals revealed a plasma cell population ([@bib118]). In addition, IgG memory cells specific to the RBD have been identified in the blood of COVID-19 patients ([@bib143]). Consistent with the development of immunity after COVID-19 infection, a recent study of SARS-CoV-2 infection in rhesus macaques found that two macaques that had resolved the primary infection were resistant to reinfection 28 days later ([@bib17]).

Due to the timing of this outbreak, it is not yet possible to know the nature and extent of long-term memory responses, but lessons may again be learned from other human CoVs. In the case of the human CoV 229E, specific IgG and nAbs are rapidly induced but wane in some individuals around a year after infection, with some residual protection to reinfection ([@bib30], [@bib226]). The lifespan of the humoral response following SARS-CoV-1 infection is also relatively short, with the initial specific IgG and nAb response to SARS-CoV-1 diminishing 2--3 years after infection and nearly undetectable in up to 25% of individuals ([@bib37], [@bib167]). A long-term study following 34 SARS-CoV-1-infected healthcare workers over a 13-year period also found that virus-specific IgG declined after several years, but the authors observed detectable virus-specific IgG 12 years after infection ([@bib118]). In the case of MERS-CoV, antibodies were detected in six of seven volunteers tested 3 years after infection ([@bib213]).

IgG specific to SARS-CoV-2 trimeric spike protein was detectable in serum up to 60 days after symptom onset, but IgG titers began decreasing by 8 weeks post symptom onset ([@bib1]). Long-term protection from reinfection may also be mediated by reactive memory B cells. A study that analyzed SARS-CoV-1 S protein-specific IgG memory cells at 2, 4, 6, and 8 months post infection found that S-specific IgG memory B cells decreased progressively about 90% from 2 to 8 months after infection ([@bib274]). A further retrospective study of 23 individuals found no evidence of circulating SARS-CoV-1-specific IgG^+^ memory B cells 6 years after infection ([@bib258]). This is in contrast to the memory T cell response, which was robustly detected based on induced IFN-γ production ([@bib258]).

Studies of common CoVs SARS-CoV-1 and MERS-CoV indicate that virus-specific antibody responses wane over time and, in the case of common CoVs, result in only partial protection from reinfection. These data suggest that immunity to SARS-CoV-2 may diminish following a primary infection, and further studies will be required to determine the degree of long-term protection ([Figure 4](#fig4){ref-type="fig"}).

### Consequences of the B Cell Response: Protection versus Enhancement {#sec1.6.3}

Several studies have demonstrated that high virus-specific antibody titers to SARS-CoV-2 are correlated with greater neutralization of virus *in vitro* and are inversely correlated with viral load in patients ([Figure 4](#fig4){ref-type="fig"}) ([@bib207], [@bib303], [@bib344]). Despite these indications of a successful neutralizing response in the majority of individuals, higher titers are also associated with more severe clinical cases ([@bib161], [@bib207], [@bib344], [@bib354]), suggesting that a robust antibody response alone is insufficient to avoid severe disease ([Figure 4](#fig4){ref-type="fig"}).

This was also observed in the previous SARS-CoV-1 epidemic, where neutralizing titers were found to be significantly higher in deceased patients compared to patients who had recovered ([@bib335]). This has led to concerns that antibody responses to these viruses may contribute to pulmonary pathology via antibody-dependent enhancement (ADE) ([Figure 4](#fig4){ref-type="fig"}). This phenomenon is observed when non-neutralizing virus-specific IgG facilitate entry of virus particles into Fc-receptor (FcR) expressing cells, particularly macrophages and monocytes, leading to inflammatory activation of these cells ([@bib262]). A study in SARS-CoV-1-infected rhesus macaques found that anti-S IgG contributed to severe acute lung injury (ALI) and massive accumulation of monocytes and macrophages in the lung ([@bib168]). Furthermore, serum containing anti-S Ig from SARS-CoV-1 patients enhanced the infection of SARS-CoV-1 in human monocyte-derived macrophages *in vitro* ([@bib329]). ADE was also reported with a monoclonal antibody isolated from a patient with MERS-CoV ([@bib286]). Somewhat reassuringly, there was no evidence of ADE mediated by sera from rats vaccinated with SARS-CoV-2 RBD *in vitro* ([@bib223]) nor in macaques immunized with an inactivated SARS-CoV-2 vaccine candidate ([@bib103]).

As of now, there is no evidence that naturally developed antibodies toward SARS-CoV-2 contribute to the pathological features observed in COVID-19. However, this possibility should be considered when it comes to experimental design and development of therapeutic strategies. Importantly, in all of the descriptions of ADE as it relates to CoV, the FcR was necessary to trigger the antibody-mediated pathology. High-dose intravenous immunoglobulin (IVIg), which may blunt ADE, has been trialed in COVID-19 patients ([@bib40], [@bib234]), but further studies are needed to determine the extent to which IVIg is safe or beneficial in SARS-CoV-2 infection. Vaccine trials will need to consider the possibility of antibody-driven pathology upon antigen rechallenge; strategies using F(ab) fragments or engineered Fc monoclonal antibodies may prove particularly beneficial in this setting ([@bib7]).

Predictors of COVID-19 Disease Risk and Severity {#sec1.7}
------------------------------------------------

With the rapidly growing number of cases in the first few months, numerous reports on predictors of COVID-19 severity with small cohorts were released. These offered clinicians and immunologists the first understanding of the clinical course and pathological processes that are associated with the novel SARS-CoV-2 infection. This section highlights key findings from those studies, with a major focus on the immune factors associated with disease risk or severity.

### Susceptibility and Risk Biomarkers {#sec1.7.1}

There are currently limited known risk factors for susceptibility to COVID-19, although this has been evaluated in several studies. Zhao et al. compared the ABO blood group distribution in a cohort of 2,173 COVID-19 patients to that of healthy controls from the corresponding regions ([@bib345]). They found blood group A to be associated with a higher risk for acquiring COVID-19 when compared to non-A blood groups; blood group O had the lowest risk for the infection. Another study demonstrated an identical association ([@bib362]), and similar results have been previously described for other viruses ([@bib166]), including SARS-CoV-1 ([@bib61]).

Several large collaborative efforts are currently underway to generate, share, and analyze genetic data to understand the links between human genetic variation and COVID-19 susceptibility and severity, the most prominent of which is the COVID-19 Host Genetics Initiative ([covid19hg.org](http://covid19hg.org){#intref0010}). These studies are supported by previous observations on SARS-CoV-1 that followed the 2003 outbreak, which have identified significant associations between genetic variants and immune phenotypes ([@bib45], [@bib289], [@bib341]). Although identifying such polymorphisms and their associated genes and pathways for SARS-CoV-2 will require large cohorts, several studies, which remain to be tested in clinical trials, have already highlighted genetic polymorphisms that may potentially impact susceptibility. These studies have focused on genetic variants that may impact the expression or function of genes important in viral entry, namely ACE2 (SARS-CoV-2 receptor) and TMPRSS2 (spike protein activator) ([@bib14], [@bib41], [@bib227], [@bib249]). Cao et al. identified variants that are potentially expression quantitative trait loci (eQTL) of ACE2 (i.e., they may potentially alter ACE2 gene expression) and analyzed their frequencies in different populations ([@bib41]). Stawiski et al. listed variants that may be critical in ACE2 binding and thereby its function and compared the frequencies of these variants within different populations ([@bib249]).

While there are several limitations to these studies, the major question is whether the utility of these biomarkers is replicable in large populations with COVID-19 clinical outcomes data and in targeted or large-scale genomic analyses that are currently underway. In addition, these studies will reveal the potential associations between genetic variants and susceptibility in a gene or loci agnostic fashion.

### Routine Bloodwork Biomarkers {#sec1.7.2}

Several routine blood and serological parameters have been suggested to stratify patients who might be at higher risk for complications to aid in allocation of healthcare resources in the pandemic ([Table 1](#tbl1){ref-type="table"} ). Serologic markers from routine bloodwork were reported by comparing patients with mild or moderate symptoms to those with severe symptoms. This includes different acute phase proteins, such as SAA (serum amyloid protein) and C-reactive protein (CRP) ([@bib140]). Interestingly, elevations in CRP appear to be unique to COVID-19 patients when compared to other viral infections. Other consistently reported markers in non-survivors are increased procalcitonin (PCT) and IL-6 levels ([@bib135]), as well as increased serum urea, creatinine, cystatin C, direct bilirubin, and cholinesterase ([@bib313]). Overall, inflammatory markers are common in severe cases of COVID-19 and appear to correlate with the severity of the symptoms and clinical outcome. Moreover, the extensive damage that occurs in specific organs of severe COVID-19 patients is possibly related to differences in the expression of ACE2 ([Figure 5](#fig5){ref-type="fig"} ) ([@bib86]).Table 1Routine Blood and Immunological Prognostic Biomarkers in COVID-19 PatientsBiomarkerPurposeRoutine BloodworkLymphocyte countPredicted the disease severity and the outcomes of hospitalized patients ([@bib255]).\
Prognostic value was confirmed in numerous studies ([@bib135], [@bib170], [@bib247], [@bib295], [@bib311], [@bib321], [@bib324], [@bib338], [@bib347]).\
Decreased continuously in non-surviving patients ([@bib291]).N/LPatients with N/L ≥3.13 were reported to be more likely to develop severe illness and to require ICU admission ([@bib171]).\
N/L on admission was a risk factor for short-term progression of patients with moderate pneumonia to severe pneumonia ([@bib93]). Confirmed to be of prognostic value in COVID-19 in several studies ([@bib247], [@bib311], [@bib357]).CRPProposed as an early biomarker of disease progression ([@bib140]). Even in early stages, CRP levels were positively correlated with lung lesions and reflected disease severity ([@bib287]). Confirmed in numerous studies ([@bib99], [@bib135], [@bib311], [@bib321], [@bib347], [@bib355]). Predicted the risk of acute myocardial injury ([@bib175], [@bib316]).LDHHigher in severe cases than in mild cases ([@bib313]). Widely proposed to have prognostic value in COVID-19 ([@bib135], [@bib311], [@bib321], [@bib347]).D-dimer (and coagulation parameters)Predicted severity independently of other variables ([@bib357]). Elevated levels and disseminated intravascular coagulation are found in non-survivors ([@bib291]). Identified patients at risk for acute cardiac injury ([@bib175]). Other coagulation parameters, such as fibrin degradation product levels, longer prothrombin time, and activated partial thromboplastin time, were also associated with poor prognosis ([@bib259]).SAASAA was proposed to be used as an auxiliary index for diagnosis as it was elevated in 80% of the patients in a small cohort ([@bib140]).NT-proBNP (N-terminal pro B type natriuretic peptide)NT-proBNP was an independent risk factor of in-hospital death in patients with severe COVID-19 ([@bib102]).Platelet countHigh platelet-to-lymphocyte ratio was associated with worse outcome ([@bib222]). Thrombocytopenia was associated with poor outcome and with incidence of myocardial injury in COVID-19 ([@bib176], [@bib240]).ImmunologicalCD4+, CD8+, and NK cell countsLower CD4+, CD8+, and NK cells in PBMCs correlated with severity of COVID-19 ([@bib202]). Validated by several studies ([@bib295], [@bib351]).PD-1 and Tim-3 expression on T cellsIncreasing PD-1 and Tim-3 expression on T cells could be detected as patients progressed from prodromal to overtly symptomatic stages ([@bib80]). Expression was higher in infected patients versus healthy controls and in ICU versus non-ICU patients in both CD4 and CD8 T cells ([@bib355]).phenotypic changes in peripheral blood monocytesThe presence of a distinct population of monocytes with high forward scatter (CD11b+, CD14+, CD16+, CD68+, CD80+, CD163+, and CD206+, which secrete IL-6, IL-10, and TNF-α) was identified in patients requiring prolonged hospitalization and ICU admission ([@bib338]). CD14+CD16+IL-6+ monocytes are increased in ICU patients ([@bib355]).IP-10, MCP-3, and IL-1raIP-10, MCP-3, and IL-1ra were, among 48 examined cytokines, the only ones that closely associated with disease severity and outcome of COVID-19 in a study by Yang et al. ([@bib324]).IL-6Associated with disease severity (hospitalization and ICU admission) and poor prognosis ([@bib58], [@bib133], [@bib170], [@bib174], [@bib291]). Increased levels were associated with higher risk of respiratory failure ([@bib327]).IL-8Positively correlated with disease severity ([@bib56], [@bib113]), with severe cases showing the highest IL-8 levels.IL-10Increased in severe or critical patients as compared to mild patients ([@bib113], [@bib357]) without a statistically significant difference between severe and critical cases ([@bib113]).IL-2RAssociated with disease severity in a study that, among other cytokines, also associated ferroprotein levels, PCT levels, and eosinophil counts with COVID-19 severity ([@bib113]).IL-1βCD14+IL-1β+ monocytes are abundant in early-recovery patients as shown in a single-cell RNA-seq analysis and thought to be associated with cytokine storm ([@bib300]). IL-1β did not correlate with disease severity in a cross-sectional study with mild, severe, and critical patients ([@bib113]).IL-4IL-4 was associated with impaired lung lesions ([@bib99]), but some reports point to a potential mediator effect ([@bib300]).IL-18In modeling immune cell interaction between DCs and B cells in late recovery COVID-19 patients, IL-18 was found to be important in B cell production of antibodies, which suggests its importance in recovery ([@bib300]).GM-CSFGM-CSF+IFN-γ+ T cells are higher in ICU than in non-ICU patients. CD14+CD16+GM-CSF+ monocytes are higher in COVID-19 patients as compared to healthy controls ([@bib355]).IL-2 and IFN-γIL-2 and IFN-γ levels were shown to be increased in severe cases ([@bib170]).anti-SARS-CoV-2 antibody levelsProlonged SARS-CoV-2 IgM positivity could be utilized as a predictive factor for poor recovery ([@bib99]). Higher anti-SARS-CoV-2 IgG levels and higher N/L were more commonly found in severe cases ([@bib336]).Figure 5ACE2 Expression in Organs and Systems Most Frequently Implicated in COVID-19 ComplicationsThe gastrointestinal tract, kidneys, and testis have the highest ACE2 expressions. In some organs, different cell types have remarkably distinct expressions; e.g., in the lungs, alveolar epithelial cells have higher ACE2 expression levels than bronchial epithelial cells; in the liver, ACE2 is not expressed in hepatocytes, Kupffer cells, or endothelial cells but is detected in cholangiocytes, which can explain liver injury to some extent. Furthermore, ACE2 expression is enriched on enterocytes of the small intestine compared to the colon.ACE2, angiotensin-converting enzyme 2; BNP, B-type natriuretic peptide; CRP, C-reactive protein; IL, interleukin; N/L, neutrophil-to-lymphocyte ratio; PT, prothrombin time; aPTT, activated partial thromboplastin time.

Lymphopenia is the most frequently described prognostic marker in COVID-19 ([Table 1](#tbl1){ref-type="table"}), and it appears to predict morbidity and mortality even at early stages ([@bib92]). Tan et al. proposed a prognostic model based on lymphocyte counts at two time points: patients with less than 20% lymphocytes at days 10--12 from the onset of symptoms and less than 5% at days 17--19 had the worst outcomes in this study ([@bib255]). Wynants et al. compared predictors of disease severity across seven studies (\>1,330 patients), highlighting CRP, neutrophil-to-lymphocyte ratio (N/L), and lactate dehydrogenase (LDH) as the most significant predictive biomarkers ([@bib311]). Furthermore, a meta-analysis of 30 COVID-19 studies with a total of 53,000 patients also attempted to identify early-stage patients with poor prognosis ([@bib347]). The most consistent findings across the different studies were elevated levels of CRP, LDH, and D-dimer, as well as decreased blood platelet and lymphocyte counts ([@bib321], [@bib357]). Systemic and pulmonary thrombi have been reported with activation of the extrinsic coagulation cascade, involving dysfunctional endothelium and monocytic infiltration ([@bib218], [@bib278]); thrombocytopenia and elevated D-dimer levels may be indicative of these coagulopathies in COVID-19 patients with important therapeutic implications ([@bib95], [@bib218]).

### Immunological Biomarkers in the Peripheral Blood {#sec1.7.3}

Immunological biomarkers are particularly important, as immunopathology has been suggested as a primary driver of morbidity and mortality with COVID-19. Several cytokines and other immunologic parameters have been correlated with COVID-19 severity ([Table 1](#tbl1){ref-type="table"}). Most notably, elevated IL-6 levels were detected in hospitalized patients, especially critically ill patients, in several studies and are associated with ICU admission, respiratory failure, and poor prognosis ([@bib58], [@bib133], [@bib174]). Increased IL-2R, IL-8, IL-10, and GM-CSF have been associated with disease severity as well, but studies are limited, and further studies with larger cohorts of patients are needed to indicate predictive power ([@bib113], [@bib355]). Conflicting results regarding IL-1β and IL-4 have been reported ([@bib99], [@bib113], [@bib300]). Although elevated cytokine concentrations have been widely described in COVID-19 patients, the vast majority (including IL-6, IL-10, IL-18, CTACK, and IFN-γ) do not seem to have prognostic value, because they do not always differentiate moderate cases from severe cases ([@bib324]). This stratification was possible with IP-10, MCP-3, and IL-1ra. While there are reports that levels of IL-6 at first assessment might predict respiratory failure ([@bib124]), other publications with longitudinal analyses demonstrated that IL-6 increases fairly late during the disease's course, consequently compromising its prognostic value at earlier stages ([@bib354]).

Liu et al. developed a web-based tool using k-means clustering to predict prognosis in terms of death or hospital discharge of COVID-19 patients using age, comorbidities (binary), and baseline log helper T cell count (TH), log suppressor T cell count (TS), and log TH/TS ratio ([@bib173]). Total T cell, helper T cell, and suppressor T cell counts were significantly lower and the TH/TS ratio was significantly higher in patients who died from infection as compared to patients who were discharged.

Importantly, most serological and immunological changes observed in severe cases are associated with disease severity but cannot necessarily serve as predictive factors, as they may not have utility in early identification of patients at higher risk. Discovery of truly predictive biomarkers and potential drivers of hyperinflammatory processes requires comprehensive profiling of asymptomatic and mild cases and longitudinal studies that are limited to date. Confounding variables including age, gender, and comorbidities may dramatically affect associations observed. In addition, direct correlation with patient viral load will be important to provide a greater understanding of underlying causes of morbidity and mortality in COVID-19 and the contribution of viral infectivity, hyperinflammation, and host tolerance ([@bib190]).

In summary, lymphopenia, increases in proinflammatory markers and cytokines, and potential blood hypercoagulability characterize severe COVID-19 cases with features reminiscent of cytokine release syndromes. This correlates with a diverse clinical spectrum ranging from asymptomatic to severe and critical cases. During the incubation period and early phase of the disease, leukocyte and lymphocyte counts are normal or slightly reduced. After SARS-CoV-2 binds to ACE2 overexpressing organs, such as the gastrointestinal tracts and kidneys, increases in non-specific inflammation markers are observed. In more severe cases, a marked systemic release of inflammatory mediators and cytokines occurs, with corresponding worsening of lymphopenia and potential atrophy of lymphoid organs, impairing lymphocyte turnover ([@bib264]).

Antivirals {#sec1.8}
----------

Antivirals are a class of small molecules that function as inhibitors of one or more stages of a virus life cycle. Because of similarities between different virus replication mechanisms, some antivirals can be repurposed against various viral infections. Currently, most of the available antiviral drugs tested against SARS-CoV-2 are small molecules previously developed against SARS-CoV-1, MERS-CoV, or other RNA and DNA viruses.

### Broad-Spectrum Antivirals {#sec1.8.1}

A number of small molecules with known antiviral activity against other human RNA viruses are being evaluated for efficacy in treating SARS-CoV-2. The ribonucleoside analog β-D-N4-hydroxycytidine (NHC) reduced viral titers and lung injury in mice infected with SARS-CoV-2 via introduction of mutations in viral RNA ([@bib235]). Further, an inhibitor of host DHODH, a rate-limiting enzyme in pyrimidine synthesis, was able to inhibit SARS-CoV-2 growth *in vitro* with greater efficacy than remdesivir or chloroquine ([@bib294], [@bib315]). Merimepodib, a non-competitive inhibitor of the enzyme inosine-5′-monophosphate dehydrogenase (IMPDH), involved in host guanosine biosynthesis, is able to suppress SARS-CoV-2 replication *in vitro* ([@bib28]). Finally, N-(2-hydroxypropyl)-3-trimethylammonium chitosan chloride (HTCC), which was previously shown to efficiently reduce infection by the less-pathogenic human CoV HCoV-NL63, was also found to inhibit MERS-CoV and pseudotyped SARS-CoV-2 in human airway epithelial cells ([@bib193]).

### Protease Inhibitors {#sec1.8.2}

Much of the antiviral computational and experimental data currently available for SARS-CoV-2 focus on targeting the 3CL or Main protease (Mpro). Two prominent drug candidates targeting the SARS-CoV-2 Mpro were designed and synthesized by analyzing the substrate binding pocket of Mpro ([@bib73]). The X-ray crystal structures of the novel inhibitors in complex with SARS-CoV-2 Mpro were resolved at 1.5 Å. Both compounds showed good pharmacokinetic activity *in vitro*, and one exhibited limited toxicity *in vivo* ([@bib73]). Multiple studies also aimed to repurpose protease inhibitors to reduce SARS-CoV-2 titers. Nine existing HIV protease inhibitors (nelfinavir, lopinavir, ritonavir, saquinavir, atazanavir, tipranavir, amprenavir, darunavir, and indinavir) were evaluated for their antiviral activity in Vero cells infected with SARS-CoV-2 ([@bib319]), and nelfinavir was the most potent at inhibiting viral replication.

### RdRp Inhibitors {#sec1.8.3}

The CoV RNA-dependent RNA polymerase (RdRp) catalyzes the synthesis of viral RNA ([@bib101]), making it essential for viral replication and a prime target for antiviral inhibitors. Remdesivir, an adenosine triphosphate analog, inhibits RdRp by binding to RNA strands and preventing additional nucleotides from being added, thereby terminating viral RNA transcription ([Figure 6](#fig6){ref-type="fig"} A) ([@bib2]). Remdesivir has been previously shown to be effective against MERS-CoV and SARS-CoV-1 infections in animal models ([@bib235], [@bib77]). Similarly, a study investigated the efficacy of remdesivir treatments on 12 rhesus macaques with SARS-CoV-2 infections ([@bib302]). Macaques treated with remdesivir showed a reduction in lung viral loads and pneumonia symptoms but no reduction in virus shedding. This study does provide evidence that if administered early enough, remdesivir may be effective at treating SARS-CoV-2 infections.Figure 6Available Therapeutic Options to Manage COVID-19 Immunopathology and to Deter Viral Propagation(A) Rdrp inhibitors (remdesivir, favipiravir), protease inhibitors (lopinavir/ritonavir), and antifusion inhibitors (arbidol) are currently being investigated in their efficacy in controlling SARS-CoV-2 infections.(B) CQ and HCQ increase the pH within lysosomes, impairing viral transit through the endolysosomal pathway. Reduced proteolytic function within lysosomes augments antigen processing for presentation on MHC complexes and increases CTLA4 expression on Tregs.(C) Antagonism of IL-6 signaling pathway and of other cytokine-/chemokine-associated targets has been proposed to control COVID-19 CRS. These include secreted factors like GM-CSF that contribute to the recruitment of inflammatory monocytes and macrophages.(D) Several potential sources of SARS-CoV-2 neutralizing antibodies are currently under investigation, including monoclonal antibodies, polyclonal antibodies, and convalescent plasma from recovered COVID-19 patients.GM-CSF, granulocyte-macrophage colony-stimulating factor; CQ, chloroquine; HCQ, hydroxychloroquine; RdRp, RNA-dependent RNA polymerase.

### Antiviral Clinical Trials {#sec1.8.4}

A large number of clinical trials using experimental antiviral drugs are currently underway. A small proportion of them are aimed at repurposing existing antivirals, including arbidol (umifenovir), a broad-spectrum antiviral that blocks viral fusion; lopinavir/ritonavir (LPV/r), a combination of anti-HIV protease inhibitors; favipiravir, an RdRp inhibitor used to treat severe influenza infections ([@bib122]); and remdesivir ([Figure 6](#fig6){ref-type="fig"}A). Chen et al. conducted a multicenter, randomized priority trial on 240 patients with confirmed COVID-19 infection to test favipiravir or arbidol ([@bib53]). Favipiravir was suggested to significantly improve symptom relief. However, the interpretation of this study is limited by a short clinical recovery window of 7 days, only 100 of 236 patients with confirmed COVID-19, and the lack of a control group.

LPV/r has previously shown efficacy in treating SARS-Cov-1 ([@bib65]), prompting an early SARS-Cov-2 clinical trial ([@bib162]). 44 patients were enrolled in a trial investigating the efficacy and safety of LPV/r (n = 21 patients), arbidol (n = 16), or control (n = 7) as treatment for mild to moderate COVID-19. At day 14 of treatment, 76.2%, 62.4%, and 71.4% of patients had a positive to negative conversion in the LPV/r, arbidol, and control groups, respectively, with no statistical significance between groups. A randomized controlled trial (RCT) with 200 severe COVID-19 patients did not observe a significant benefit of LPV/r either ([@bib39]). However, a study that looked at the impact of earlier administration of LPV/r treatment showed that when treatment of LPV/r was started within 10 days of symptom onset, a shorter duration of virus shedding was observed. Thus, timing of LPV/r administration may be critical to its efficacy ([@bib320]).

In a multicenter clinical study assessing the compassionate use of remdesivir in severe COVID-19 patients, 53 patients across several countries were treated with remdesivir for 10 days ([@bib115]). 68% of the 53 patients who received remdesivir showed clinical improvement assessed through improved oxygen support or extubations. Without a proper control group, limited conclusions can be drawn with regards to the efficacy of remdesivir from this study. The measured 68% clinical improvement may be in line with average clinical improvement across patients treated with standard of care ([@bib162]). A small RCT in China with 237 severe COVID-19 patients randomized 2:1 to remdesivir versus placebo demonstrated no significant benefit in time to clinical improvement ([@bib296]). Almost simultaneously, preliminary results from a larger National Institute of Allergy and Infectious Diseases (NIAID) RCT with more than 1,000 patients were announced with remdesevir to be associated with quicker time to recovery: 11 days compared with 15 days ([@bib153]). A non-significant benefit in mortality was also noted, and the trial was stopped early to allow access to remdesivir in the placebo arm. Complete safety data and full publication are awaited, but this study offers encouraging results and has resulted in an FDA emergency use authorization for remdesivir in hospitalized COVID-19 patients.

Therapeutic Immunomodulation for COVID-19 Treatment {#sec1.9}
---------------------------------------------------

### Chloroquine: Modes of Action and Immunological Impact {#sec1.9.1}

Chloroquine (CQ) and its derivative hydroxychloroquine (HCQ) have gained traction as possible therapeutics for COVID-19. Both drugs are used as antimalarial agents and as immunomodulatory therapies for rheumatologic diseases. However, the application of CQ and HCQ to COVID-19 stems from their past use as antivirals ([@bib230]), including for SARS-CoV-1 ([@bib146], [@bib279]). CQ and HCQ interfere with lysosomal activity and have been reported to have immunomodulatory effects. CQ augments antigen processing for MHC class I and II presentation, directly inhibits endosomal TLR7 and TLR9, and enhances the activity of regulatory T cells ([@bib105], [@bib177], [@bib231], [@bib268], [@bib269]). Early studies involving *in vitro* infection of host cells with SARS-CoV-2 demonstrated that both CQ and HCQ significantly impact endosomal maturation, resulting in increased sequestration of virion particles within endolysosomes. However, there has been conflicting evidence whether CQ is more potent than HCQ in reducing viral load ([@bib172], [@bib291], [@bib326]). Notably, one group reported that treatment of infected cells with HCQ before and during infection significantly reduced viral load, suggesting that combined prophylactic and therapeutic HCQ use yields maximum efficacy ([@bib70]). To better understand host immune responses to treatment, one group compared bulk transcriptomic changes in primary PBMCs treated with HCQ for 24 h to PBMCs from confirmed SARS-CoV-2 positive patients and controls, followed by a comparison of HCQ-treated primary macrophages to BAL and postmortem lung biopsies from COVID-19 patients ([@bib72]). Across all comparisons, there was minimal overlap between host differential gene expression and genes altered by *in vitro* HCQ treatment. Thus, the potential mechanistic action of HCQ in the context of SARS-CoV-2 remains poorly defined.

### Evaluation of HCQ Efficacy in Clinical Trials {#sec1.9.2}

Despite the apparent widespread use of HCQ and CQ to treat COVID-19 ([Figure 6](#fig6){ref-type="fig"}B), few controlled clinical trials have been performed so far and thus the potential benefits of these drugs for COVID-19 remains controversial. One of the earliest trials (2020-000890-25) was a single-arm, open-label trial of 600 mg daily HCQ in 20 COVID-19 patients. They reported that HCQ alone, or in combination with the antibiotic azithromycin (AZ), reduced viral load by day 6 ([@bib107]). A follow-up trial in 80 patients treated with HCQ and AZ reported that 93% of patients had a negative PCR result on day 8 of treatment, and 81.3% were discharged within 10 days of treatment. However, it is important to note that both trials had no control arms ([@bib108]). Rigorous statistical analyses by others that accounted for the patients excluded from the original analysis found limited evidence for HCQ monotherapy ([@bib136], [@bib182]). A double-blind RCT assessed HCQ monotherapy in the treatment of mild COVID-19 (ChiCTR2000029559) ([@bib60]). A total of 62 patients were enrolled; the treatment arm received 400 mg HCQ daily over 5 days. By day 6, patients who received HCQ had clinical resolution on average 1 day earlier than controls; no patients progressed to severe disease compared to four patients in the control arm. In a smaller RCT that treated 30 patients with mild COVID-19 (NCT04261517) with 400 mg HCQ for 7 days, there were no significant differences in the number of patients with negative PCR results on day 7 (all but one positive), median duration of hospitalization, time to fever resolution, or progression of disease on chest computed tomography (CT) ([@bib55]). The largest RCT to date enrolled 150 patients with mild COVID-19 across 16 centers in an open-label trial of HCQ and standard of care (ChiCTR2000029868). There were no significant differences between groups in conversion to negative SARS-CoV-2 RT-PCR result on day 28 or rate of symptom resolution; there were significantly more adverse events in the HCQ arm, though largely non-serious; they reported some evidence for faster normalization of C-reactive protein in the patients who received HCQ plus standard of care, but this finding was not significant ([@bib260]). A meta-analysis including most of the studies described here found no clinical benefits to patients receiving standard of care plus an HCQ regimen ([@bib232]).

Two studies have assessed HCQ efficacy in severe COVID-19. In a prospective study of 11 patients who had received 600 mg HCQ over 10 days with AZ on days 1--5, there were several patients with worsening clinical status and one death; 8 of 10 patients had a positive PCR result on day 10 ([@bib196]). An ongoing double-blind RCT of patients with severe COVID-19 (NCT04323527) randomized 81 patients into high-dose HCQ (600 mg 2× per day for 10 days) or low-dose (450 mg/day for 5 days) treatment groups ([@bib23]). Recruitment into the high-dose arm was halted prematurely due to poor safety outcomes. There was no significant difference in negative PCR results on day 4 or need for mechanical ventilation on day 6. Taken together, the clinical trials performed thus far to evaluate the efficacy of HCQ ± AZ for COVID-19 have not demonstrated clear evidence of clinical benefit in patients with severe disease. A search of [ClinicalTrials.gov](http://ClinicalTrials.gov){#intref0015} on April 27, 2020 found 140 clinical trials investigating HCQ. This number is rapidly growing, indicating the heightened interest in this therapeutic and pressing need for evidence-based recommendations.

### Corticosteroids for COVID-19 Therapy {#sec1.9.3}

Because of their anti-inflammatory activity, corticosteroids (CSs) are an adjuvant therapy for ARDS and cytokine storm. However, the broad immunosuppression mediated by CS does raise the possibility that treatment could interfere with the development of a proper immune response against the virus. A meta-analysis of 5,270 patients with MERS-CoV, SARS-CoV-1, or SARS-CoV-2 infection found that CS treatment was associated with higher mortality rate ([@bib325]). A more recent meta-analysis of only SARS-CoV-2 infection assessed 2,636 patients and found no mortality difference associated with CS treatment, including in a subset of patients with ARDS ([@bib100]). Other studies have reported associations with delayed viral clearance and increased complications in SARS and MERS patients ([@bib229]). In fact, the interim guidelines updated by the WHO on March 13, 2020 advise against giving systemic corticosteroids for COVID-19 ([@bib305]). Yet, new data from COVID-19 are conflicting.

One group reported no significant difference in time to viral clearance between patients who received methylprednisolone orally (mild disease) or intravenously (i.v.) (severe) and those who did not ([@bib89]). Retrospective studies from groups in China report that patients who were transferred to the ICU were less likely to have received CSs ([@bib291]) and that patients with ARDS who received methylprednisolone had reduced mortality risk ([@bib308]). In contrast, another retrospective analysis found that patients who received CSs were more likely to have either been admitted to the ICU or perished, although the CS-treated group also had significantly more comorbidities ([@bib292]). A smaller observational study of 31 patients found no association between corticosteroid treatment and time to viral clearance, length of hospital stay, or symptom duration ([@bib334]). A larger study of adjuvant CSs in 244 patients with critical COVID-19 found no association with 28-day mortality; subgroup analysis of patients with ARDS found no association between treatment with CSs and clinical outcomes ([@bib184]). They also found that increased dosage was significantly associated with increased mortality risk. A retrospective review of 46 patients, of whom 26 received i.v. methylprednisolone, found that early, low-dose administration significantly improved SpO2 and chest CT, time to fever resolution, and time on supplemental oxygen therapy ([@bib297]). Others have published perspectives in support of early ([@bib155]) and short-term, low-dose administration ([@bib233]) based on anecdotal evidence but not clinical trials. Most of the current data on CS use in COVID-19 are from observational studies and support either modest clinical benefit or no meaningful effects. Larger RCTs are necessary to understand the risks and benefits of CSs for these patients; there are 22 trials evaluating various corticosteroids registered on [ClinicalTrials.gov](http://ClinicalTrials.gov){#intref0020} as of April 27, 2020.

### Cytokine-Directed Therapy in COVID-19 {#sec1.9.4}

#### Recombinant IFN as an Antiviral Treatment {#sec1.9.4.1}

One of the first defenses of the human body against RNA viruses like SARS-CoV-2 is the release of types I and III IFNs. It is important to note that type I IFN (IFNα/β) receptors are ubiquitously expressed, so IFNα/β signaling can result in not only antiviral effects, but also the activation of immune cells that potentially exacerbate pathogenesis. In contrast, type III IFN (also known as IFNλ) signals mainly in epithelial cells, as well as in a restricted pool of immune cells. Because type III IFNs have immunomodulatory functions, subsequent signaling could induce a potent antiviral effect without enhancing pathogenic inflammation ([@bib10], [@bib219]).

Recently, there has been a growing interest in the potential therapeutic impact of modulating the IFN response to disable COVID-19 pathogenesis. Before the current pandemic, groups have studied the role of IFNs in other betacoronavirus infections. One study of 40 patients with SARS-CoV-1 infection described unresolved elevated type I IFNs and ISGs in those with poor outcomes ([@bib31]). Others report that exogenous type I IFN does not improve outcomes when given with ribavirin in patients with MERS-CoV infection ([@bib13]), suggesting that the role of IFN as a therapeutic or prophylactic option may be strain or species specific ([@bib236]). Interestingly, a recent study by Mount Sinai virology groups revealed that type I IFN signaling is impaired in the early response to SARS-CoV-2; *in vitro*, SARS-CoV-2 may be more susceptible to type I IFN than SARS-CoV-1 is ([@bib22]). Based on additional evidence that IFN responses to betacoronaviruses are altered as compared to other respiratory viruses ([@bib22], [@bib47], [@bib206]), trials of IFN-I/III administration have been initiated (NCT04343976, NCT04331899).

#### Cytokine Blockade {#sec1.9.4.2}

Hyperinflammatory responses and elevated levels of inflammatory cytokines, including IL-6, -8, and -10, have been shown to correlate with COVID-19 severity ([@bib59], [@bib80], [@bib113], [@bib198], [@bib284], [@bib317]). The drivers of this cytokine storm remain to be established, but they are likely triggered initially by a combination of viral PAMPs and host danger signals. The heterogeneous response between patients suggests other factors are involved, possibly including the SARS-CoV-2 receptor, ACE2 ([@bib125]).

Several studies have begun to report the cellular programs that may contribute to the cytokine storm detected in COVID-19 patients. One group reported that in the context of generalized lymphopenia, certain subsets of CD4 T cells that express GM-CSF and IL-6 are more abundant in severe COVID-19 patients than in COVID-19 patients who do not require intensive care ([@bib355]). Reports that other major proinflammatory cytokines (TNF-α, IFN-ɣ, IL-2) and chemokines (CCL2, CCL3, CCL4) are elevated underscore a potentially pathogenic T~H~1/2 program in COVID-19 ([@bib80], [@bib109]). Histological and single-cell analyses identified monocytes and macrophages as other potent sources of inflammatory cytokines in COVID-19 cytokine storm ([@bib59], [@bib109], [@bib152], [@bib198], [@bib355]). Studies of other betacoronavirus infections, including SARS-CoV-1 and MERS-CoV, have also identified similar hyperactivation of monocytes, macrophages, and DCs as a driver of cytokine-mediated immunopathology in humans ([@bib63], [@bib64], [@bib134], [@bib150], [@bib288], [@bib304], [@bib317], [@bib355]).

Following preliminary reports of IL-6 as a critical cytokine in COVID-19-associated CRS, monoclonal antibodies that target the IL-6 signaling pathway have been proposed as therapeutic candidates ([@bib198]) ([Figure 6](#fig6){ref-type="fig"}C). The commercial anti-IL-6R antibodies tocilizumab (Actemra) and sarilumab (Kevzara) and the anti-IL-6 antibody siltuximab (Sylvant) are now being tested for efficacy in managing COVID-19 CRS and pneumonia in 13 ongoing clinical trials ([Table 2](#tbl2){ref-type="table"} ). To date, only one group has reported preliminary results from a cohort of 20 COVID-19 patients treated with a single administration of tocilizumab (400 mg, i.v.), along with lopinavir, methylprednisolone, and oxygen therapy (ChiCTR2000029765) ([@bib317]). The single observation study found recuperated lymphocyte counts in 10 of 19 patients and resolution of lung opacities in 19 of 20 patients on chest CT; 19 of 20 patients were discharged. All patients experienced an improvement in symptoms, and no subsequent pulmonary infections were reported. A second report described an association between use of tocilizumab and reduced likelihood of ICU admission and mechanical ventilation. Still, in 30 declining patients with severe COVID-19 pneumonia, this retrospective study did not report significant improvement in mortality on weighted analysis ([@bib228]). Nevertheless, these studies are encouraging, but like other treatment approaches, larger RCTs are needed.Table 2Clinical Trials Evaluating the Efficacy of IL-6/IL-6R Blockade TherapyClinical TrialInterventionNCT04331795 (COVIDOSE)\
NCT04320615 (COVACTA)\
NCT04332913 (TOSCA)\
NCT04317092 (TOCOVID-19)\
NCT04335071 (CORON-ACT)\
NCT04315480\
ChiCTR2000029765tocilizumabNCT04315298sarilumabNCT04310228tocilizumab\
favipiravirNCT04306705 (TACOS)tocilizumab\
continuous renal replacement therapy\
standard of careNCT04332094 (TOCOVID)tocilizumab\
azithromycin\
hydroxychloroquineNCT04341870 (CORIMUNO-VIRO)sarilumab\
azithromycin\
hydroxychloroquineNCT0433z638 (COV-AID)tocilizumab\
siltuximab\
anakinra\
standard of care

In addition to the IL-6 signaling pathway, other cytokine- and chemokine-associated elements, including IL-1R, GM-CSF, and the chemokine receptor CCR5, have been proposed as potential targets for blockade to manage COVID-19 CRS ([Figure 6](#fig6){ref-type="fig"}C). Finally, complement activation was shown to be overactivated in lungs of COVID-19 patients. Although results from the randomized trial are not yet published, anti-C5a monoclonal antibody therapy showed benefits in two critically ill COVID-19 patients ([@bib104]).

Neutralizing Antibodies and Convalescent Plasma Therapy for COVID-19 {#sec1.10}
--------------------------------------------------------------------

While vaccines are being developed to educate a person's immune system to make their own nAbs against SARS-CoV-2, there is interest in using adoptive transfer of nAbs as a therapeutic approach ([Figure 6](#fig6){ref-type="fig"}D). This strategy has already proven to be effective against SARS-CoV-1 ([@bib38], [@bib126], [@bib263], [@bib212], [@bib250], [@bib358]) and MERS-CoV ([@bib96], [@bib141], [@bib328]). In the case of SARS-CoV-2, these efforts are primarily centered on identifying nAbs made during natural infections or generating nAbs through animal vaccination approaches.

### nAbs Derived from COVID-19 Patients {#sec1.10.1}

Patients who have recovered from SARS-CoV-2 infection are one potential source of nAbs ([@bib52], [@bib143], [@bib282], [@bib303], [@bib331]). In an effort to obtain these nAbs, scientists sorted RBD-specific memory B cells and cloned their heavy and light variable regions to express recombinant forms of the corresponding antibodies ([@bib52], [@bib143]). Four of the antibodies produced in these studies (31B5, 32D4, P2C-2F6, P2C-1F11) showed high neutralizing potential *in vitro*, and all inhibited ACE2-RBD binding. Successful antibody-mediated neutralization of SARS-CoV-2 seemed to be dependent on the inhibition of ACE2/RBD binding. However, Chen et al. showed that nearly all antibodies derived from serum of 26 recovered patients bound to S1 and RBD, with only three actually inhibiting ACE2/RBD binding ([@bib52]). Of note, a SARS-CoV-1-derived neutralizing antibody (47D11) ([@bib290]) and a single-chain antibody against SARS-CoV-2 (n3130) ([@bib310]) have also been shown to neutralize SARS-CoV-2 without inhibiting ACE2/RBD binding. Thus, blocking this interaction may not be a prerequisite for an effective SARS-CoV-2 nAb. The generation of a hybridoma producing a monoclonal nAb against SARS-CoV-2 provides the potential for a therapeutic Ab that can be directly administered to patients to block ongoing infection and potentially even as a prophylactic ([Figure 6](#fig6){ref-type="fig"}D).

### SARS-CoV-1 nAbs Also Neutralize SARS-CoV-2 {#sec1.10.2}

SARS-CoV-1 and SARS-CoV-2 consensus sequences share about 80% identity ([@bib254]). Thus, a wide range of SARS-CoV-1 nAbs have been tested for crossreactivity with SARS-CoV-2, as they could help speed up the development of potential COVID-19 treatments. In a recent study, antibodies were isolated from the memory B cells of an individual who recovered from SARS-CoV-1 infection. While 8 out of 25 isolated antibodies could bind SARS-CoV-2 S protein, one of them (s309; see [Table 3](#tbl3){ref-type="table"} ) also neutralizes SARS-CoV-2 ([@bib217]). The combination of s309 with a weakly neutralizing antibody that could bind another RBD epitope led to enhanced neutralization potency. In addition, CR3022 ([Table 3](#tbl3){ref-type="table"}) was found to bind SARS-CoV-2 RBD ([@bib272]), but this antibody did not neutralize SARS-CoV-2 ([@bib331]). Computational simulations identified three amino acids that could be modified on CR3022 to enhance its binding affinity with SARS-CoV-2 RBD ([@bib111]), potentially augmenting its neutralization potential.Table 3Strategies to Isolate SARS-CoV-2 Neutralizing AntibodiesAb SourceCloneTargetType of AntibodyNeutralizationInhibition of ACE2/RBD BindingReferenceDerived from COVID-19 patients31B532D4RBDhuman monoclonalyesyes[@bib52]P2C-2F6P2C-1F11RBDhuman monoclonalyesyes[@bib143]Derived from SARS-CoV-1 patientsCR3022RBDhuman monoclonalnono[@bib272], [@bib331], [@bib111]S309RBDhuman monoclonalyesno[@bib217]Derived from SARS-CoV-1 or MERS-CoV-1 animal modelsR325R302R007S1rabbit monoclonalyesno[@bib253]47D11S1recombinant human monoclonal (derived from hybridomas of immunized transgenic H2L2 mice)yesno[@bib290]VHH-72-FcSFc-fusion derived from camelids VHHyesyes[@bib307]Spolyclonal mouse antibodiesyesN/A[@bib282], [@bib331]OtherACE2-FcRBDACE2-Fc fusionyesN/A[@bib156], [@bib163]RBD-FcACE2RBD-Fc fusionyesN/A[@bib163]N3130S1human monoclonal single domain antibody isolated by phage displayyesno[@bib310]IVIgN/Apolyclonal human IVIgN/AN/A[@bib81], [@bib234]F(ab′)~2~RBDhorse polyclonalyesN/A[@bib210][^1]

### nAbs Derived from Animals {#sec1.10.3}

Animal models represent another tool to generate nAbs against SARS-CoV-2 ([Table 3](#tbl3){ref-type="table"}). In one study, the authors developed a protocol to synthetize human nanobodies, smaller antibodies that only contain a variable heavy (VH) chain as first described in camelids ([@bib310]) ([Figure 6](#fig6){ref-type="fig"}D). Another antibody isolated from camelids immunized with SARS-CoV-1 and MERS-CoV S proteins then fused to a human Fc fragment showed neutralization potential against SARS-CoV-2 (VHH-72-Fc) ([@bib307]). Genetically modified mice with humanized antibody genes can also be used to generate therapeutic monoclonal antibodies, as successfully experimented against Ebola virus ([@bib158]). Similar studies are now focused on the use of SARS-CoV-2 or derivatives to generate highly effective nAb in animal models, which can be directly given to infected patients, and efforts are already underway with estimates of clinical trials of pooled antibody cocktails beginning in early summer by Regeneron. Finally, another approach to nAb development is to fuse ACE2 protein and the Fc part of antibodies, as they would bind RBD and potentially be crossreactive among other CoVs ([Figure 6](#fig6){ref-type="fig"}D). Indeed, an ACE2-Fc ([@bib156]) and an RBD-Fc ([@bib163]) have been shown to neutralize both SARS-CoV-1 and SARS-CoV-2 *in vitro*.

### Convalescent Plasma Therapy {#sec1.10.4}

Although recombinant nAbs could provide an effective treatment, they will require a significant time investment to develop, test, and bring production to scale before becoming widely available to patients. A faster strategy consists of transferring convalescent plasma (CP) from previously infected individuals that have developed high titer nAbs that target SARS-CoV-2 ([Figure 6](#fig6){ref-type="fig"}D). Despite the current lack of appropriately controlled trials, CP therapy has been previously used and shown to be beneficial in several infectious diseases, such as the 1918 influenza pandemic ([@bib185]), H1N1 influenza ([@bib137]), and SARS-CoV-1 ([@bib12]). Thanks to the development of serological tests ([@bib8], [@bib29], [@bib314], [@bib339]), recovered COVID-19 patients can be screened to select plasma with high antibody titers.

Some studies and case reports on CP therapy for COVID-19 have evaluated the safety and the potential effectiveness of CP therapy in patients with severe disease ([@bib5], [@bib87], [@bib214], [@bib237], [@bib337]) ([Table 4](#tbl4){ref-type="table"} ). These studies were neither controlled nor randomized, but they suggest that CP therapy is safe and can have a beneficial effect on the clinical course of disease. Further controlled trials are needed to determine the optimal timing and indication for CP therapy. CP therapy has also been proposed for prophylactic use in at-risk individuals, such as those with underlying health conditions or health care workers exposed to COVID-19 patients. The FDA has approved the use of CP to treat critically ill patients ([@bib261]). Determining when to administer the CP is also of great importance, as a study in SARS-CoV-1 patients showed that CP was much more efficient when given to patients before day 14 day of illness ([@bib62]), as previously shown in influenza ([@bib185]). This study also showed that CP therapy was more efficient in PCR-positive, seronegative patients. The amount of plasma and number of transfusions needed requires further investigation ([Table 4](#tbl4){ref-type="table"}).Table 4Clinical Studies of Convalescent Plasma Therapy in COVID-19 PatientsPatient CharacteristicsStart of CP TherapyResultsReference5 severe patients (30--70 yo)between 10 and 22 days after hospital admissionbody temperature normalized within 3 days in 4 of 5 patients[@bib237]clinical improvementviral loads became negative within 12 days of the transfusionnAb titers increased10 severe patients (34--78 yo)median 16.5 dpodisappearance of clinical symptoms after 3d[@bib87]chest CT improvedelevation of lymphocyte counts in patients with lymphocytopenia.increase in SaO2 in all patientsresolution of SARS-CoV-2 viremia in 7 patientsincrease in neutralizing antibody titers in 5 patients4 critical patients (31--73 yo)at degradation of symptoms,\
between 11 and 19 days after hospital admissionclinical improvement[@bib337]reduced viral loadchest CT improved1 moderate patient, 2 critical patients12 dpo, 27 dpoviral detection negative 4 days after CP[@bib214]clinical improvement of 2 patients2 severe patients (67 and 71 yo)7 dpo or 22 dpoclinical improvement[@bib5]reduced viral loadchest CT improved[^2]

Overall, CP therapy seems to be associated with improved outcomes and appears to be safe, but RCTs are needed to confirm this. Several clinical trials are currently in progress worldwide ([@bib20]).

Vaccine Development {#sec1.11}
-------------------

The devastating effects of the pandemic spread of SARS-CoV-2 in a globally naive population has resulted in unprecedented efforts to rapidly develop, test, and disseminate a vaccine to protect against COVID-19 or to mitigate the effects of SARS-CoV-2 infection. Although vaccination has a long and successful history as an effective global health strategy, there are currently no approved vaccines to protect humans against CoVs ([@bib9]). Previous work after the SARS-CoV-1 and MERS-CoV epidemics has provided a foundation on which many current efforts are currently building upon, including the importance of the S protein as a potential vaccine. Diverse vaccine platforms and preclinical animal models have been adapted to SARS-CoV-2, facilitating fast-moving and robust progress in creating and testing SARS-CoV-2 vaccine candidates. A number of vaccine candidates are already being tested in clinical trials, and more are continuing to progress toward clinical testing.

### The S Protein as a Vaccine Target {#sec1.11.1}

Since SARS-CoV-1 first emerged, the S protein has been favored as the most promising target for vaccine development to protect against CoV infection. This particular viral protein has important roles in viral entry and in stimulating the immune response during natural infection and in vaccination studies of both SARS-CoV-1 and MERS-CoV ([@bib85], [@bib246], [@bib353]), which has also been confirmed for SARS-CoV-2 ([@bib282]). The S protein has been found to induce robust and protective humoral and cellular immunity, including the development of nAbs and T cell-mediated immunity ([@bib85]). In animal models, correlates of protection against SARS-CoV-1 infection appear to be induction of nAbs against the S protein, although antibodies to other proteins have been detected, such as those against nucleoprotein (N) and ORF3a ([@bib221], [@bib251]). nAbs are also believed to protect against infection by blocking receptor binding and viral entry, which has been shown with pseudovirus-based neutralization assays ([@bib83], [@bib201]). Studies of SARS-CoV-1 indicate that T cell response against the S protein correlates with nAb titers and dominated the T cell response after natural infection, which also induced T cells active against the membrane (M) and N proteins, that memory T cell responses can persist even 11 years after infection, and that memory CD8+ T cells can protect mice from lethal challenge in the absence of memory CD4+ T cells and memory B cells ([@bib159], [@bib200]). RBD-specific antiviral T cell responses have also been detected in people who have recovered from COVID-19, further validating its promise as a vaccine target ([@bib26], [@bib83]).

### Epitope Mapping {#sec1.11.2}

Although the antibodies targeting the RBD of the S protein have greater potential for providing cross-protective immunity, other fragments of the S protein and additional viral proteins have been investigated as target epitopes, especially for T cells. Researchers have taken advantage of the genetic similarity between SARS-CoV-2 and SARS-CoV-1 and MERS-CoV and bioinformatics approaches to rapidly identify potential B and T cell epitopes in the S and other proteins, with many studies providing data regarding antigen presentation and antibody-binding properties and one study looking into the predicted evolution of epitopes ([@bib3], [@bib19], [@bib21], [@bib90], [@bib116], [@bib180], [@bib348]). While the S protein has been found to be the most immunodominant protein in SARS-CoV-2, the M and N proteins also contain B and T cell epitopes, including some with high conservation with SARS-CoV-1 epitopes ([@bib116]).

### Vaccine Pipeline {#sec1.11.3}

For SARS-CoV-1 and MERS-CoV, animal studies and phase I clinical trials of potential vaccines targeting the S protein had encouraging results, with evidence of nAb induction and induction of cellular immunity ([@bib165], [@bib189], [@bib195]). These findings are being translated into SARS-CoV-2 vaccine development efforts, hastening the progress drastically. The WHO provided a report in April that reported 63 vaccine candidates in preclinical testing and three in clinical testing ([@bib306]). A recent search on May 1, 2020 on [ClinicalTrials.gov](http://ClinicalTrials.gov){#intref0025} revealed 10 registered vaccine candidates ([Table 5](#tbl5){ref-type="table"} ). The University of Pittsburgh is also looking to move their microneedle array vaccine candidate containing a codon-optimized S1 subunit protein into clinical trials ([@bib148]). Sanofi and GlaxoSmithKline (GSK) have recently reported their intent to collaborate and bring together Sanofi's baculovirus expression system, which is used to produce the influenza virus vaccine, Flublok, to create an S protein vaccine adjuvanted with GSK's AS03. Sinovac Biotech will also enter testing in a clinical trial in China after it was found to protect rhesus macaques from viral challenge without signs of detectable immunopathology ([@bib103]). Although some of these vaccine candidates are based on platforms that have been used or tested for other purposes, there remain questions regarding their safety and immunogenicity, including the longevity of any induced responses, that will require continual evaluation.Table 5Vaccine Candidates Currently Registered for Clinical TrialsCandidateDesignDeveloperSimilar StrategyClinicalTrials.gov IdentifiermRNA-1273LNP-encapsulated mRNA for full-length S proteinModernaTXCMV ([@bib142]), ZKV ([@bib211])[NCT04283461](NCT04283461){#intref0045}BNT162a1, b1, b2, c2LNP-encapsulated mRNA vaccines with different formats of RNA and targets, two for larger S sequence and two for optimized RBDBioNTech SE and Pfizer[NCT04368728](NCT04368728){#intref0050}INO-4800DNA vaccine for full-length S proteinInovio PharmaceuticalsMERS-CoV ([@bib195]), HPV ([@bib276])[NCT04336410](NCT04336410){#intref0055}Ad5-nCoVadenovirus type 5 encoding full-length S proteinCanSino BiologicsEBV ([@bib359], [@bib360])[NCT04313127](NCT04313127){#intref0060} (phase I)\
[NCT04341389](NCT04341389){#intref0065} (phase II)ChAdOx1 nCoV-19adenovirus encoding full-length S proteinUniversity of OxfordMERS-CoV ([@bib6]), IAV ([@bib11])[NCT04324606](NCT04324606){#intref0070}COVID-19 LV-SMENP-DCdendritic cells infected with lentivirus expressing SMENP minigenes to express COVID-19 antigens, together with activated CTLsShenzhen Geno-Immune Medical Institute[NCT04276896](NCT04276896){#intref0075}COVID-19 aAPCsaAPCs infected with lentivirus expressing minigenes to express COVID-19 antigensShenzhen Geno-Immune Medical Institute[NCT04299724](NCT04299724){#intref0080}bacTRL-Spike-1live bacteria delivering plasmid encoding S proteinSymvivo Corporationtherapeutics reviewed ([@bib49])[NCT04334980](NCT04334980){#intref0085}PiCoVaccinactivated SARS-CoV-2 vaccineSinovac BiotechHAV, IAV, IBV, poliovirus, rabies virus[NCT04352608](NCT04352608){#intref0090}SARS-CoV-2 rSspike protein nanoparticle vaccine with or without Matrix-M adjuvantNovavax[NCT04368988](NCT04368988){#intref0095}[^3]

### Challenges {#sec1.11.4}

Although the development of a vaccine to protect against SARS-CoV-2 infection has progressed at an unprecedented rate and produced an impressive volume of candidates for testing, many challenges lie ahead. The prior knowledge gained after SARS-CoV-1 was first discovered in 2003, and the subsequent emergence of MERS-CoV in 2012 provided a significant jumpstart, but the progress of SARS-CoV-2 vaccine development has already far outstripped the point of the blueprint created before COVID-19 became a pandemic. While a variety of platforms are simultaneously being innovated or adapted, they each have strengths and limitations, many of which relate to the delicate balance between safety and immunogenicity. Many shortcuts have been taken and will continue to be taken due to the urgency of the ongoing COVID-19 pandemic, but significant concerns need to be addressed. One such concern involves the accumulating data supporting the initial assessment that COVID-19 is disproportionately severe in older adults. In conjunction with the large body of work related to immune senescence, these findings indicate that vaccine design should take into consideration the impact of aging on vaccine efficacy ([@bib205]). Furthermore, questions remain regarding the possibility of antibody-dependent enhancement of COVID-19, with *in vitro* experiments, animal studies, and two studies of COVID-19 patients supporting this possibility ([@bib36], [@bib265], [@bib336], [@bib344]). Assuming vaccine candidates that can safely induce protective immune responses are identified, additional major hurdles will be the production and dissemination of a vaccine. For some types of vaccines, large-scale production will not be as much of an issue, and infrastructure already in place to produce current Good Manufacturing Practice (cGMP)-quality biologics can be repurposed, but this will only be applicable to a subset of the candidates ([@bib266]). In order to address the urgent need and stem the COVID-19 pandemic, regulatory agencies need to continue to support rapid testing and progression of vaccine candidates, companies need to disseminate important findings directly and openly, and researchers need to investigate correlates of protection using in-depth immune monitoring of patients with a broad range of clinical presentations and clinical trial participants. The newly announced Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) is designed to bring together numerous governmental and industry entities to help address this need.

Concluding Remarks {#sec1.12}
------------------

The rapid spread of SARS-CoV-2 and the unprecedented nature of COVID-19 has demanded an urgency in both basic science and clinical research, and the scientific community has met that call with remarkable productivity. Within months, there has been a significant generation of scientific knowledge that has shed some light on the immunology of SARS-CoV-2 infections. Studies of past coronavirus outbreaks involving SARS-CoV-1 and MERS-CoV have provided a foundation for our understanding. The pathology of severe cases of COVID-19 does indeed resemble certain immunopathologies seen in SARS-CoV-1 and MERS-CoV infections, like CRS.

However, in many other ways, immune responses to SARS-CoV-2 are distinct from those seen with other coronavirus infections. The emerging epidemiological observation that significant proportions of individuals are asymptomatic despite infection not only reflects our current understanding that SARS-CoV-2 has a longer incubation period and higher rate of transmission than other coronaviruses, but also speaks to significant differences in the host immune response. Therefore, it is imperative that immune responses against SARS-CoV-2 and mechanisms of hyperinflammation-driven pathology are further elucidated to better define therapeutic strategies for COVID-19. Here, we reviewed the recent literature and highlighted hypotheses that interrogate mechanisms for viral escape from innate sensing, for hyperinflammation associated with CRS and inflammatory myeloid subpopulations, for lymphopenia marked by T cell and NK cell dysfunction, and for correlates of protection and their duration, among others. Still, additional studies are needed to address how these immune differences across patients or between different types of coronavirus infections dictate who succumbs to disease and who remains asymptomatic. Existing studies of SARS-CoV-1 and MERS-CoV and ongoing studies of SARS-CoV-2 will likely provide a robust framework to fulfill that unmet need.
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[^1]: N/A, not assessed.

[^2]: yo, years old; dpo, days post onset of symptoms.

[^3]: aAPCs, artificial antigen-presenting cells; CMV, cytomegalovirus; EBV, Ebola virus; HAV, hepatitis A virus; HPV, human papillomavirus; IAV, influenza A virus; IBV, influenza B virus; LPN, lipid nanoparticle; ZKV, Zika virus.
